[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 36850
1. Trejo Amador U, Granados Cosme JA, Ortiz Hernández L, Delgado Sánchez G: [Social Differences in Proper Detection of Cervical Uterine Cancer among Employees at a University in Mexico City]. Rev Esp Salud Publica; 2005 Jun 01;79:403-414

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Diferencias sociales de la detección oportuna de cáncer cérvico uterino en las mujeres trabajadoras de una Universidad de la Ciudad de México.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28272388.001).
  • [ISSN] 2173-9110
  • [Journal-full-title] Revista espanola de salud publica
  • [ISO-abbreviation] Rev. Esp. Salud Publica
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  • [Keywords] NOTNLM ; Cervical cancer / Inequalities / Life style / Mexico / Social conditions / Socioeconomic factors / Socioeconomic level.
  •  go-up   go-down


2. Ansari M, St-Onge G, Krajinovic M: [Pharmacogenomics of acute lymphoblastic leukemia]. Med Sci (Paris); 2007 Nov;23(11):961-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pharmacogenomics of acute lymphoblastic leukemia].
  • [Transliterated title] Pharmacogénétique de la leucémie lymphoblastique aiguë
  • Pharmacogenomics of acute lymphoblastic leukemia (ALL) evolved rapidly in the past few years.
  • Leukemia is the most common cancer affecting children, with ALL comprising 80 % of all leukemia cases.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18021708.001).
  • [ISSN] 0767-0974
  • [Journal-full-title] Médecine sciences : M/S
  • [ISO-abbreviation] Med Sci (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; E7WED276I5 / 6-Mercaptopurine; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2); YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


3. Mateo J, Abarzuza R, Núñez E, Cristóbal JA: [Bilateral optic nerve infiltration in acute lymphoblastic leukemia in remission]. Arch Soc Esp Oftalmol; 2007 Mar;82(3):167-70
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bilateral optic nerve infiltration in acute lymphoblastic leukemia in remission].
  • [Transliterated title] Infiltración bilateral del nervio óptico en un caso de leucemia aguda linfoblástica de células T en remisión.
  • CASE REPORT: An 18-year-old male affected by acute lymphoblastic leukemia (ALL) after having reached complete remission after chemotherapy developed bilateral optic nerve infiltration.
  • [MeSH-major] Leukemic Infiltration. Optic Nerve / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diagnosis, Differential. Fatal Outcome. Fundus Oculi. Humans. Male. Papilledema / diagnosis. Prognosis. Recurrence. Remission Induction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17357894.001).
  • [ISSN] 0365-6691
  • [Journal-full-title] Archivos de la Sociedad Española de Oftalmología
  • [ISO-abbreviation] Arch Soc Esp Oftalmol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


Advertisement
4. Benítez Velazco A, González García FM, Albalá González MD, Pacheco Capote C, Latre Romero JM: [Bone scintigraphy with 99mTc-MDP in a patient with acute lymphoblastic leukemia initially diagnosed of Still's disease]. Rev Esp Med Nucl; 2005 Sep-Oct;24(5):319-21
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bone scintigraphy with 99mTc-MDP in a patient with acute lymphoblastic leukemia initially diagnosed of Still's disease].
  • [Transliterated title] Gammagrafía ósea con 99mTc-MDP en un paciente con leucemia aguda linfoblástica diagnosticado inicialmente de enfermedad de Still.
  • We present a 43-year-old male, who was admitted with the diagnosis of Adult-onset Still's disease, after several months of arthralgias, febricula and loss of weight.
  • Scintigraphic findings oriented to the performance of a bone marrow biopsy with diagnosis of acute lymphoblastic leukemia.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / radionuclide imaging. Radiopharmaceuticals. Still's Disease, Adult-Onset / diagnosis. Technetium Tc 99m Medronate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16194464.001).
  • [ISSN] 0212-6982
  • [Journal-full-title] Revista española de medicina nuclear
  • [ISO-abbreviation] Rev Esp Med Nucl
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; X89XV46R07 / Technetium Tc 99m Medronate
  •  go-up   go-down


5. Readers panel - All for one and one for all. Nurs Stand; 2009 Apr 22;23(33):26-27

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Readers panel - All for one and one for all.
  • : Our experts consider a hot topic of the day.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27991101.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


6. Martins A, Cairoli H, Domínguez P, Martin S, Ortiz C, Potasznik J, Schenone N: [Nephromegaly: as unusual presentation of acute lymphoblastic leukemia in an infant]. Arch Argent Pediatr; 2008 Jun;106(3):263-5
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Nephromegaly: as unusual presentation of acute lymphoblastic leukemia in an infant].
  • [Transliterated title] Nefromegalia: forma de presentación infrecuente de leucemia linfoblástica aguda en un lactante.
  • Nephromegaly in infancy may be due to several causes, being the most relevant: renal polycystic autosomic recessive disease, venous renal thrombosis, deposit diseases, kidney tumors, nephrotic congenital syndrome and neoplastic infiltration.
  • Although renal infiltration is relatively frequent in acute lymphoblastic leukemia, nephromegaly is an unusual form of presentation in this pathology.
  • Acute Lymphoblastic Leukemia is diagnosed, initiating the corresponding chemotherapic treatment.
  • [MeSH-major] Kidney / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18695841.001).
  • [ISSN] 1668-3501
  • [Journal-full-title] Archivos argentinos de pediatría
  • [ISO-abbreviation] Arch Argent Pediatr
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Argentina
  •  go-up   go-down


7. Brentjens RJ: Cellular therapies in acute lymphoblastic leukemia. Curr Opin Mol Ther; 2009 Aug;11(4):375-82
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cellular therapies in acute lymphoblastic leukemia.
  • The majority of adult patients with acute lymphoblastic leukemia (ALL) will die from the disease.
  • Although the prognosis for pediatric patients is significantly better than for adult patients with ALL, the prognosis for patients with relapsed or refractory disease is poor in all cases.
  • Allogeneic hematopoietic stem cell transplantation (allo-HSCT) from a related donor offers a significant therapeutic benefit for pediatric patients, although the benefit of this therapy to adults with ALL is less established.
  • Although treatment with donor-derived T-cells, so-called 'donor lymphocyte infusion', has demonstrated poor outcomes in patients with relapsed ALL following HSCT, modified adoptive T-cell regimens, including the infusion of enriched tumor-targeted donor T-cells and genetically targeted T-cells, are currently under clinical investigation.
  • In addition, the resistance of ALL tumor cell lines to NK-cell-mediated lysis may be overcome by the genetic modification of NK cells to target ALL tumor cell antigens, and this approach will be evaluated in an upcoming clinical trial.
  • Whether these novel adoptive cell therapies will ultimately result in improved clinical outcomes remains to be determined.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2005 Feb 15;105(4):1622-31 [15507526.001]
  • [Cites] Ann Hematol. 2004 Oct;83(10):667-9 [15300405.001]
  • [Cites] Biol Blood Marrow Transplant. 2009 Feb;15(2):257-65 [19167686.001]
  • [Cites] Bone Marrow Transplant. 1997 Feb;19(4):393-4 [9051252.001]
  • [Cites] Haematologica. 2005 Oct;90(10):1346-56 [16219571.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4075-86 [15353542.001]
  • [Cites] Cancer Res. 2009 May 1;69(9):4010-7 [19383914.001]
  • [Cites] Curr Opin Immunol. 2009 Apr;21(2):215-23 [19327974.001]
  • [Cites] Br J Haematol. 2008 Dec;143(5):641-53 [18950462.001]
  • [Cites] N Engl J Med. 2004 Nov 25;351(22):2276-85 [15564544.001]
  • [Cites] Cytotherapy. 2009;11(3):341-55 [19308771.001]
  • [Cites] Blood. 1995 Sep 1;86(5):2041-50 [7655033.001]
  • [Cites] Leukemia. 2007 Sep;21(9):1907-14 [17611565.001]
  • [Cites] J Immunother. 2009 Feb-Mar;32(2):169-80 [19238016.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2816-25 [15254049.001]
  • [Cites] Blood. 2006 Apr 1;107(7):2643-52 [16352804.001]
  • [Cites] Leukemia. 2004 Apr;18(4):676-84 [14961035.001]
  • [Cites] Blood. 2008 Nov 1;112(9):3574-81 [18606875.001]
  • [Cites] Lancet. 2008 Mar 22;371(9617):1030-43 [18358930.001]
  • [Cites] Blood Cells Mol Dis. 2004 Jul-Aug;33(1):83-9 [15223016.001]
  • [Cites] J Immunol. 2000 Feb 15;164(4):1873-80 [10657636.001]
  • [Cites] J Formos Med Assoc. 1998 Jan;97(1):55-8 [9481066.001]
  • [Cites] Bone Marrow Transplant. 2006 Jan;37(2):155-63 [16284608.001]
  • [Cites] Blood. 2007 Jun 1;109(11):5058-61 [17317850.001]
  • [Cites] Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5426-35 [17855649.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10995-1004 [17108138.001]
  • [Cites] Hematol Oncol Clin North Am. 2000 Dec;14(6):1353-66, x [11147227.001]
  • [Cites] Bone Marrow Transplant. 2008 Mar;41(5):483-93 [18026156.001]
  • [Cites] Blood. 2009 Mar 26;113(13):3110-8 [19059878.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1637-44 [12393484.001]
  • [Cites] Blood. 2004 Feb 1;103(3):767-76 [12958064.001]
  • [Cites] Best Pract Res Clin Haematol. 2008 Sep;21(3):467-83 [18790450.001]
  • [Cites] Bone Marrow Transplant. 2007 Aug;40(4):339-47 [17572712.001]
  • [Cites] Blood. 2005 Apr 15;105(8):3051-7 [15632206.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Jan;12(1):1-30 [16399566.001]
  • [Cites] Cancer. 2006 Jun 15;106(12):2657-63 [16703597.001]
  • [Cites] Blood. 2009 Feb 19;113(8):1631-8 [19104080.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3447-54 [15753458.001]
  • [Cites] Bone Marrow Transplant. 2005 Jul;36(2):163-9 [15937507.001]
  • [Cites] Science. 2002 Mar 15;295(5562):2097-100 [11896281.001]
  • [Cites] Blood. 2005 Jul 1;106(1):376-83 [15755898.001]
  • [Cites] Leukemia. 2006 Oct;20(10):1819-28 [16932339.001]
  • [Cites] N Engl J Med. 1998 Oct 22;339(17):1186-93 [9780338.001]
  • [Cites] Nat Rev Cancer. 2003 Jan;3(1):35-45 [12509765.001]
  • [Cites] Bone Marrow Transplant. 2008 Aug;42 Suppl 1:S18-S24 [18724292.001]
  • [Cites] Blood. 2007 Feb 1;109(3):944-50 [17032921.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Dec;14(12):1394-400 [19041062.001]
  • [Cites] Immunogenetics. 2000 Feb;51(2):99-107 [10663572.001]
  • [Cites] Blood. 2007 Sep 15;110(6):1924-32 [17505014.001]
  • [Cites] Nat Med. 2003 Mar;9(3):279-86 [12579196.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1827-33 [18048644.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Curr Oncol Rep. 2004 Sep;6(5):339-47 [15291974.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1325-31 [16269610.001]
  • [Cites] N Engl J Med. 2004 Nov 25;351(22):2265-75 [15564543.001]
  • [Cites] Br J Haematol. 2005 Dec;131(5):579-87 [16351633.001]
  • [Cites] Blood. 2002 Mar 15;99(6):2009-16 [11877273.001]
  • [Cites] Annu Rev Med. 1999;50:369-86 [10073284.001]
  • [Cites] Blood. 2009 Mar 26;113(13):2902-5 [19179301.001]
  • [Cites] Blood. 1994 Dec 1;84(11):3948-55 [7524753.001]
  • [Cites] Bone Marrow Transplant. 2008 Mar;41(5):473-81 [18176612.001]
  • [Cites] Blood. 2004 Dec 1;104(12):3813-20 [15280199.001]
  • [Cites] Bone Marrow Transplant. 2000 Sep;26(5):511-6 [11019840.001]
  • [Cites] Semin Hematol. 2009 Jan;46(1):64-75 [19100369.001]
  • (PMID = 19649982.001).
  • [ISSN] 2040-3445
  • [Journal-full-title] Current opinion in molecular therapeutics
  • [ISO-abbreviation] Curr. Opin. Mol. Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K08 CA095152; United States / NCI NIH HHS / CA / R01 CA138738; United States / NCI NIH HHS / CA / CA95152; United States / NCI NIH HHS / CA / P30 CA008748; United States / NCI NIH HHS / CA / CA138738; United States / NCI NIH HHS / CA / P01 CA059350; United States / NCI NIH HHS / CA / CA59350
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 65
  • [Other-IDs] NLM/ NIHMS746468; NLM/ PMC4694559
  •  go-up   go-down


8. Cheok MH, Pottier N, Kager L, Evans WE: Pharmacogenetics in acute lymphoblastic leukemia. Semin Hematol; 2009 Jan;46(1):39-51
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacogenetics in acute lymphoblastic leukemia.
  • Progress in the treatment of acute lymphoblastic leukemia (ALL) in children has been remarkable, from a disease being lethal four decades ago to current cure rates exceeding 80%.
  • However, despite these high cure rates, the annual number of children whose leukemia relapses after their initial therapy remains greater than that of new cases of most types of childhood cancers.
  • These studies illustrate the promise of pharmacogenomics to further advance the treatment of human cancers, with childhood leukemia serving as a paradigm.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2000 Apr;14(4):567-72 [10764140.001]
  • [Cites] Nature. 2000 Jun 15;405(6788):847-56 [10866211.001]
  • [Cites] Nature. 2000 Jun 15;405(6788):857-65 [10866212.001]
  • [Cites] Nat Genet. 2000 Oct;26(2):135-7 [11017062.001]
  • [Cites] Semin Hematol. 2000 Oct;37(4):381-95 [11071360.001]
  • [Cites] Clin Chem. 2001 Feb;47(2):164-72 [11159763.001]
  • [Cites] Nature. 2001 Feb 15;409(6822):928-33 [11237013.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2293-301 [11304783.001]
  • [Cites] J Clin Oncol. 2001 Jun 1;19(11):2948-58 [11387368.001]
  • [Cites] Genome Res. 2001 Jul;11(7):1262-8 [11435409.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7225-32 [11585759.001]
  • [Cites] Science. 2001 Nov 23;294(5547):1669-70 [11721042.001]
  • [Cites] Nat Rev Genet. 2001 Dec;2(12):930-42 [11733746.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2002;42:113-33 [11807167.001]
  • [Cites] Nat Rev Genet. 2002 May;3(5):391-7 [11988764.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):3144-50 [12036927.001]
  • [Cites] Science. 2002 Jun 21;296(5576):2225-9 [12029063.001]
  • [Cites] Biochim Biophys Acta. 2002 Jul 18;1587(2-3):164-73 [12084458.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):133-43 [12086872.001]
  • [Cites] Curr Opin Pharmacol. 2002 Dec;2(6):723-9 [12482737.001]
  • [Cites] N Engl J Med. 2003 Feb 6;348(6):529-37 [12571261.001]
  • [Cites] N Engl J Med. 2003 Feb 6;348(6):538-49 [12571262.001]
  • [Cites] Haematologica. 2003 Mar;88(3):353-4 [12651279.001]
  • [Cites] Nat Genet. 2003 Apr;33(4):518-21 [12652300.001]
  • [Cites] Nat Genet. 2003 May;34(1):85-90 [12704389.001]
  • [Cites] Nat Med. 2003 May;9(5):510-1 [12724758.001]
  • [Cites] Science. 2003 Jul 4;301(5629):102-5 [12843395.001]
  • [Cites] Pharmacogenetics. 2003 Sep;13(9):577-80 [12972956.001]
  • [Cites] Nat Biotechnol. 2003 Oct;21(10):1233-7 [12960966.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2951-9 [12730115.001]
  • [Cites] Nat Rev Genet. 2003 Dec;4(12):1001-8 [14631360.001]
  • [Cites] Cell Death Differ. 2004 Feb;11(2):165-74 [14576768.001]
  • [Cites] Pharmacogenomics J. 2004;4(1):66-72 [14647408.001]
  • [Cites] Cell. 2004 Jan 23;116(2):281-97 [14744438.001]
  • [Cites] Nat Genet. 2004 Mar;36(3):257-63 [14770183.001]
  • [Cites] Nat Genet. 2004 Mar;36(3):214-5 [14988717.001]
  • [Cites] Hum Mol Genet. 2004 Apr 1;13 Spec No 1:R57-64 [14764619.001]
  • [Cites] Mol Cell Biol. 2004 Apr;24(8):3347-58 [15060156.001]
  • [Cites] Nature. 2004 May 27;429(6990):464-8 [15164072.001]
  • [Cites] Cell Death Differ. 2004 Jul;11 Suppl 1:S45-55 [15243581.001]
  • [Cites] Pharmacogenetics. 2004 Aug;14(8):557-67 [15284538.001]
  • [Cites] N Engl J Med. 2004 Aug 5;351(6):533-42 [15295046.001]
  • [Cites] J Clin Oncol. 2004 Oct 1;22(19):3930-6 [15459215.001]
  • [Cites] J Biol Chem. 1980 Jun 25;255(12):5776-88 [6892914.001]
  • [Cites] Am J Hum Genet. 1980 Sep;32(5):651-62 [7191632.001]
  • [Cites] J Clin Invest. 1985 Sep;76(3):907-12 [2413074.001]
  • [Cites] N Engl J Med. 1986 Feb 20;314(8):471-7 [3456079.001]
  • [Cites] J Steroid Biochem. 1987;27(1-3):201-8 [3501039.001]
  • [Cites] Blood. 1990 Jul 1;76(1):44-9 [1694703.001]
  • [Cites] Lancet. 1990 Jul 28;336(8709):225-9 [1973780.001]
  • [Cites] J Pediatr. 1991 Dec;119(6):985-9 [1960624.001]
  • [Cites] Annu Rev Genet. 1991;25:281-314 [1687498.001]
  • [Cites] Blood. 1994 Jul 15;84(2):564-9 [7517720.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Feb 14;92(4):949-53 [7862671.001]
  • [Cites] Nat Biotechnol. 2005 Mar;23(3):377-83 [15765094.001]
  • [Cites] Leukemia. 2002 Aug;16(8):1437-42 [12145682.001]
  • [Cites] Steroids. 2005 May-Jun;70(5-7):407-17 [15862824.001]
  • [Cites] J Natl Cancer Inst. 2005 May 4;97(9):643-55 [15870435.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4752-8 [15713801.001]
  • [Cites] Nat Rev Cancer. 2001 Nov;1(2):99-108 [11905809.001]
  • [Cites] Pharmacogenetics. 2002 Apr;12(3):181-2 [11927832.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1033-4 [11937185.001]
  • [Cites] J Clin Invest. 1996 Jan 1;97(1):73-80 [8550853.001]
  • [Cites] Mol Cell Biol. 1997 Feb;17(2):895-905 [9001244.001]
  • [Cites] Ann Intern Med. 1997 Apr 15;126(8):608-14 [9103127.001]
  • [Cites] Blood. 1997 Oct 1;90(7):2723-9 [9326239.001]
  • [Cites] N Engl J Med. 1998 Feb 19;338(8):499-505 [9468466.001]
  • [Cites] Leukemia. 1998 Mar;12(3):346-52 [9529129.001]
  • [Cites] Blood. 1999 May 1;93(9):2817-23 [10216075.001]
  • [Cites] Cancer Res. 1999 Jun 1;59(11):2532-5 [10363967.001]
  • [Cites] Lancet. 1999 Jul 3;354(9172):34-9 [10406363.001]
  • [Cites] Blood. 1999 Aug 15;94(4):1209-17 [10438708.001]
  • [Cites] Science. 1999 Oct 15;286(5439):531-7 [10521349.001]
  • [Cites] J Clin Invest. 2005 Jan;115(1):110-7 [15630450.001]
  • [Cites] Cancer Res. 2005 Jan 1;65(1):291-9 [15665306.001]
  • [Cites] Science. 2005 Feb 18;307(5712):1072-9 [15718463.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2482-7 [15781665.001]
  • [Cites] JAMA. 2005 Mar 23;293(12):1485-9 [15784872.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3053-8 [15833833.001]
  • [Cites] Cancer Cell. 2005 Apr;7(4):375-86 [15837626.001]
  • [Cites] Pharmacogenet Genomics. 2005 May;15(5):277-85 [15864128.001]
  • [Cites] Blood. 2005 Jul 15;106(2):717-20 [15797993.001]
  • [Cites] Nat Genet. 2005 Aug;37(8):878-82 [16041371.001]
  • [Cites] Nature. 2005 Oct 27;437(7063):1299-320 [16255080.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Annu Rev Med. 2006;57:119-37 [16409140.001]
  • [Cites] Leukemia. 2006 Feb;20(2):239-46 [16341039.001]
  • [Cites] Leukemia. 2006 Jan;20(1):9-17 [16281070.001]
  • [Cites] Blood. 2006 Jul 15;108(2):711-7 [16822902.001]
  • [Cites] Blood. 2006 Aug 1;108(3):1050-7 [16627760.001]
  • [Cites] Haematologica. 2006 Aug;91(8):1113-6 [16870553.001]
  • [Cites] Science. 2006 Sep 29;313(5795):1929-35 [17008526.001]
  • [Cites] Cancer Cell. 2006 Oct;10(4):331-42 [17010674.001]
  • [Cites] Nat Biotechnol. 2006 Sep;24(9):1151-61 [16964229.001]
  • [Cites] Clin Pharmacol Ther. 2006 Nov;80(5):468-76 [17112803.001]
  • [Cites] Science. 2007 Jan 26;315(5811):525-8 [17185560.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):758-64 [17344859.001]
  • [Cites] Blood. 2007 May 1;109(9):3929-35 [17218380.001]
  • [Cites] Science. 2007 Apr 27;316(5824):550-1 [17463274.001]
  • [Cites] Blood. 2007 May 15;109(10):4151-7 [17264302.001]
  • [Cites] Nature. 2007 May 10;447(7141):161-5 [17495918.001]
  • [Cites] Nat Genet. 2007 Jul;39(7 Suppl):S7-15 [17597783.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1271-7 [17456722.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Aug 14;104(33):13513-8 [17686970.001]
  • [Cites] Blood. 2007 Sep 1;110(5):1429-38 [17495134.001]
  • [Cites] Hum Mol Genet. 2007 Oct 1;16(19):2261-71 [17616514.001]
  • [Cites] Leukemia. 2007 Oct;21(10):2128-36 [17673902.001]
  • [Cites] Haematologica. 2007 Nov;92(11):1561-4 [18024406.001]
  • [Cites] Methods. 2008 Jan;44(1):22-30 [18158129.001]
  • [Cites] Blood. 2008 Mar 15;111(6):2984-90 [18182569.001]
  • [Cites] Blood. 2008 Apr 1;111(7):3692-700 [18096764.001]
  • [Cites] Blood. 2008 May 1;111(9):4496-9 [18285546.001]
  • [Cites] PLoS Med. 2008 Apr 15;5(4):e83 [18416598.001]
  • [Cites] PLoS One. 2008;3(5):e2144 [18478092.001]
  • [Cites] Pharmacogenet Genomics. 2008 Jun;18(6):507-14 [18496130.001]
  • [Cites] J Natl Cancer Inst. 2008 Dec 17;100(24):1792-803 [19066270.001]
  • [Cites] J Clin Invest. 2007 Apr;117(4):1049-57 [17380207.001]
  • [Cites] J Natl Cancer Inst. 1999 Dec 1;91(23):2001-8 [10580024.001]
  • [Cites] Int J Hematol. 1999 Dec;70(4):268-77 [10643153.001]
  • [Cites] Mol Cell Biol. 2000 Mar;20(6):2004-13 [10688647.001]
  • (PMID = 19100367.001).
  • [ISSN] 0037-1963
  • [Journal-full-title] Seminars in hematology
  • [ISO-abbreviation] Semin. Hematol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R37 CA036401-25; United States / NCI NIH HHS / CA / R37 CA36401; United States / NIGMS NIH HHS / GM / U01 GM061393; United States / NCI NIH HHS / CA / R01 CA078224; United States / NCI NIH HHS / CA / R37 CA036401; United States / NCI NIH HHS / CA / CA21765; United States / NIGMS NIH HHS / GM / U01 GM61393; United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / CA036401-25; United States / NCI NIH HHS / CA / R01 CA78224
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 120
  • [Other-IDs] NLM/ NIHMS89418; NLM/ PMC2665795
  •  go-up   go-down


9. Bates J: Nursing fever. Nurs Stand; 2007 Mar 07;21(26):28

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nursing fever.
  • : Job at risk? Facing redundancy?
  • Aren't we all?
  • Every now and then I daydream of early retirement: leisurely breakfasts with the papers, splashing out on luxury trips with my NHS pension.
  • Yes, the worry is making me hallucinate.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27967434.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


10. McGough G: Gardening initiative is a positive example for us all. Nurs Stand; 2009 Oct 07;24(5):32

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gardening initiative is a positive example for us all.
  • : I enjoyed Carol Davis's depiction of the therapeutic benefits of gardening (features September 16).
  • Research has shown that gardening - or even minimal involvement in a green space - can help with patients' recovery, and this needs to be encouraged.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28026490.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


11. Fowell M: 'damaged' nurses require support and not exclusion. Nurs Stand; 2010 Oct 27;25(8):32

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 'damaged' nurses require support and not exclusion.
  • : Further to your news story, 'Regulator reveals plans to prevent enrolment of "damaged" students' (October 20), I am concerned by any plans to cut certain people out of society like a cancer.
  • Health care is all about helping people become independent and productive achievers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28034104.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


12. Black S: The power of compassion. Nurs Stand; 2008 Oct 22;23(7):70-71

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The power of compassion.
  • : If you are thinking of becoming a nurse or have just embarked on a nursing course, one of the main characteristics you hope to bring to the role is likely to be compassion.
  • After all, compassion is what nurses do, isn't it?

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28006377.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


13. Nurses have rights too. Nurs Stand; 2006 Nov 22;21(11):1

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nurses have rights too.
  • : Nursing is a profession that deals with the vulnerable.
  • Nurses have to be trusted by everyone they deal with, including their colleagues, peers and, above all, the public.
  • That overwhelmingly they are trusted, and that they rarely fail in their responsibilities and duties, is a testament to their professionalism.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28001881.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


14. Allen D: Standard life-In these uncertain days, Daniel Allen shares his 'future-proofing' tips to help nurses toughen up. Nurs Stand; 2006 Nov 08;21(9):25

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Standard life-In these uncertain days, Daniel Allen shares his 'future-proofing' tips to help nurses toughen up.
  • : Are you future-proofed? Me neither.
  • All I can deal with is the here and now.
  • But everywhere I look people are talking about future-proofing their practice.
  • GPs are at it, police officers, lawyers, teachers - even, I suspect, clairvoyants.
  • What is it all about and should nurses be doing it, too?

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27986006.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


15. Maternal alcohol intake linked to leukaemia in childhood. Nurs Stand; 2007 Aug 29;21(51):17

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Maternal alcohol intake linked to leukaemia in childhood.
  • : More than one alcoholic drink a day during pregnancy might be associated with the development of acute lymphoblastic leukaemia in the subsequent child.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28001545.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


16. Smith J, Benjamin M, Yim JH, James RL, Ramanathan RK, Anthony SP, Borad M, Bay RC, Piper BF, Tibes R: Prospective evaluation of patient perceptions and willingness to undergo pharmacodynamic and pharmacokinetic tests in early phase oncology trials. J Clin Oncol; 2009 May 20;27(15_suppl):6587

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 6587 Background: Increasing numbers of clinical trials include optional or mandatory pharmaco-dynamic and -kinetic assays.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963864.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Vicus D, Beiner M, Klachook S, Le L, Ginsburg O, Laframboise S, Mackay H: Dysgerminoma of the ovary 35 years on: A single institutional experience. J Clin Oncol; 2009 May 20;27(15_suppl):e16523

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 40 pts (62.5%) presented with FIGO stage IA disease; 3 (4.7%) stage IB; 6 (9.4%) stage IC; 2 (3.1%) stage II; and 13 (20.3%) at stage III, 1 unknown.
  • 17 pts received chemotherapy, 15 adjuvant and 2 for residual disease (all post 1988); 8 for stage I, 1 for stage II, and 8 for stage III.
  • 6 (9.2%) pts recurred all within 19 months of initial diagnosis.
  • 5 of the 6 pts that recurred had stage IA disease treated with a unilateral oophorectomy, 1 received adjuvant EP.
  • 1 pt with stage IIIC disease recurred following bilateral oophorectomy + hysterectomy and radiotherapy.
  • Treatment of recurrent disease was by salvage surgery and chemotherapy (3 pts), radiotherapy (2 pts), and EP (1 pt).
  • Recurrences occured within 2 years of diagnosis and are treatable.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960796.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Morris B, Khan R, Ledet D, Howell C, Pui C, Hudson M, Ness K: Neurological morbidity in survivors of childhood acute lymphoblastic leukemia (ALL). J Clin Oncol; 2009 May 20;27(15_suppl):9529

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurological morbidity in survivors of childhood acute lymphoblastic leukemia (ALL).
  • METHODS: After obtaining IRB approval, all long-term ALL survivors (≥ 5 years since diagnosis) aged 6-28 years who remained active patients at our institution were identified.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964517.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Zuo Z, Jones DM, Thomas DA, O'Brien S, Ravandi F, Kantarjian HM, Medeiros LJ, Luthra R, Chen SS: A nine-gene predictor of therapy response in adult Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL). J Clin Oncol; 2009 May 20;27(15_suppl):7014

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A nine-gene predictor of therapy response in adult Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL).
  • Median disease-free survival among the optimal and relapse groups were 12 and 5 months respectively (p = 0.002).
  • There was no statistical difference in age, initial peripheral blood white cell and BM blast counts, and initial normalized BCR/ABL1 levels between groups.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961387.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Shepard RC, Talluto CC, Jacob G: Phase I study results of nanomolecular liposomal annamycin in refractory ALL. J Clin Oncol; 2009 May 20;27(15_suppl):7066

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study results of nanomolecular liposomal annamycin in refractory ALL.
  • : 7066 Background: There continues to be no effective second-line therapy for refractory AML or ALL and the cure rate with current therapy has not significantly improved in decades.
  • The first-line therapy for adult AML has remained the same 7 + 3 that it was a generation ago.
  • Annamycin was specifically synthesized to overcome MDR and to have little to no cardiac toxicity when given as a nanomolecular liposomal entity.
  • METHODS: We performed a phase I multi-center, open-label, MTD study of nanomolecular liposomal annamycin in patients with refractory ALL.
  • The secondary objective was to study the MDR-1 encoded P-1u70 glycoprotein expression in correlation with CD34 expression and MDR-1 MRP mRNA levels in refractory ALL patients before and after receiving liposomal annamycin.
  • RESULTS: Thirty patients were enrolled on the study.
  • The MTD was determined to be 150 mg/m2/day for 3 days.
  • Eight of the patients completed 1 cycle of the 3 days of treatment.
  • Of these 8 subjects, 5 (62%) had an efficacy signal.
  • All 5 completely cleared circulating blasts.
  • Three subjects also cleared bone marrow blasts.
  • Of these 3, 1 went on to a successful bone marrow transplant.
  • The other 2 had tumor lysis syndrome and unfortunately expired.
  • Other than the tumor lysis syndromes, there was only 1 SAE definitely related to the study drug which was a grade 3 mucositis but there were also 3 other SAEs of grade 3 or 4 mucositis probably related to the study drug which comprised the MTD determination.
  • There were no reports of cardiac toxicity.
  • CONCLUSIONS: Nanomolecular liposomal annamycin appears to be effective through its innate resistance to MDR even as a single agent in refractory adult ALL.
  • We are now testing it in a phase I study in children and young adults with refractory ALL or AML.
  • [Table: see text].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961442.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Iacobucci I, Storlazzi C, Lonetti A, Ferrari A, Messina M, Cilloni D, Papayannidis C, Baccarani M, Foà R, Martinelli G: IKZF1 (IKAROS) deletions as a prognostic marker in BCR-ABL1 positive acute lymphoblastic leukemia patients: A GIMEMA ALL WP Report. J Clin Oncol; 2009 May 20;27(15_suppl):11005

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IKZF1 (IKAROS) deletions as a prognostic marker in BCR-ABL1 positive acute lymphoblastic leukemia patients: A GIMEMA ALL WP Report.
  • : 11005 Expression of BCR-ABL1 in hematopoietic stem cells can alone induce a chronic myeloid leukemia (CML) but cooperating oncogenic lesions are required for the generation of a blastic leukemia.
  • To identify oncogenic sub-microscopic lesions that cooperate with BCR-ABL1 to induce ALL, by high resolution single nucleotide polymorphism (SNP) arrays (250K NspI and SNP 6.0, Affymetrix) we studied 106 patients (pts) with de novo adult BCR-ABL1-positive ALL.
  • The most frequent somatic copy number alteration was deletion on 7p12 of IKZF1 (68/106, 64%), which encodes the transcription factor Ikaros required for the earliest stages of lymphoid lineage commitment.
  • Gene expression profiling analysis of pts with IKZF1 deletion vs wild-type pts identified a unique signature characterized by a down-regulation of genes involved in pre-B-cell differentiation (e.g.
  • VPREB1, VPREB3, IGLL3, BLK), demonstrating that genomic IKZF1 alterations have a strong impact on trascriptoma and contribute to an impaired B-cell differentiation.
  • Univariate analysis showed that the IKZF1 deletion is a negative prognostic marker influencing the cumulative incidence of relapse (10.1 months for pts with deletion vs 56.1 months for wild-type pts, p=0.0103) and disease-free survival (DFS) (10.1 months vs 32.1 months, respectively, p=0.0229).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964054.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Luong NV, Kantarjian HM, Faderl SH, Thomas DA, Vu KD: Occurence of venothromboembolism (VTE) in patients (pts) with acute lymphocytic leukemia (ALL), Burkitt's leukemia/lymphoma (BL), or lymphoblastic leukemia (LL). J Clin Oncol; 2009 May 20;27(15_suppl):7059

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occurence of venothromboembolism (VTE) in patients (pts) with acute lymphocytic leukemia (ALL), Burkitt's leukemia/lymphoma (BL), or lymphoblastic leukemia (LL).
  • Although neoplastic diseases are known risk factors for the development of VTE, little is known about the incidence and predisposing factors of VTE among leukemia patients (pts).
  • In a multivariate model, significant predictors of VTE were age 40-59 yrs, plt count 50-99 x 10<sup>9</sup>/L, diagnosis of Ph-positive ALL, history of VTE, and OCP/HRT use.
  • In addition to traditional risk factors, disease-specific features may also predispose pts to higher VTE risk.
  • Further studies should be done in other leukemias to establish guidelines in the prevention and management of VTE in pts with leukemia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961450.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Latreille J, Samson A, Tran U, Mimeault C, Boily C, Laflamme B, Loutfi A: Implementation of an integrated cancer care network. J Clin Oncol; 2009 May 20;27(15_suppl):e17564

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 2004, a team evaluation process was initiated by the Direction de la lutte contre le cancer (ministry of health) to help implement this program.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963842.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Policzer J, Kinzbrunner B, Tanis D: Seasonal mortality in terminally ill cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):6575

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this paper, we compare seasonal variation in death rates for terminally ill cancer patients to terminally ill patients who are "frail," i.e., those with neurodegenerative disease, general debility, or chronic heart failure.
  • The 72,066 records were analyzed using a three-way analysis of variance (season, place of care, diagnosis) with Bonferroni correction for post-hoc comparisons.
  • These include a smaller "symptom burden" than frail patients, who frequently have comorbid disease(s) and who are often unable to make their needs known; less compromised immune systems; more aggressive medical treatment; better nutrition; a strong support system (particularly from family and caregivers); and increased sensitivity to factors that may prolong survival, e.g., timely immunizations and even the avoidance of crowds in winter months.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963828.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Carbone K: School nurse father is a shining example to us all. Nurs Stand; 2010 Oct 20;25(7):33

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] School nurse father is a shining example to us all.
  • : What a wonderful letter from 12-year-old Elizabeth Watson (October 13) describing her school nurse father as a hero.
  • It made my day.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28019635.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


26. Kamoi K, Kawauchi A, Miki T, Aron M, Remer E, Haber G, Berger A, Crouzet S, Ricardo B, Gill I: Laparoscopic renal cryoablation: Risk factor analysis to predict oncologic outcomes with minimum 5-year follow-up. J Clin Oncol; 2009 May 20;27(15_suppl):5094

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the 69 patients with biopsy-proven renal cell cancer (median follow-up 81 mos; range 60-132 mos), 5-year overall, disease-specific, and disease- free survival was 75%, 92%, and 82%, respectively, while 10-year overall, disease-specific, and disease-free survival was 46%, 83%, and 79%, respectively.
  • Relative risk of patients who has a history of radical nephrectomy for RCC treatment was 4.1 (95% CIs, 1.2 to 13.4), and 5.4 (95% CIs, 1.2 to 27.7) for disease-free survival and disease-specific survival, respectively.
  • Disease-specific survival of 92% at 5-years and 83% at 10-years is possible.
  • Preceding radical nephrectomy for RCC treatment was the only independent predicting factor for both disease-free and disease-specific survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964294.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Rousseau M, Guevremont P, Chasen M, Spicer J, Eckert E, Alcindor T, Ades S, Ferri LE: The management of dysphagia in esophageal cancer patients undergoing neoadjuvant chemotherapy: Is invasive tube feeding required? J Clin Oncol; 2009 May 20;27(15_suppl):9613

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The management of dysphagia in esophageal cancer patients undergoing neoadjuvant chemotherapy: Is invasive tube feeding required?
  • : 9613 Background: The dysphagia commonly associated with esophageal cancer often interferes with patient tolerance of neo-adjuvant chemotherapy.
  • Surgical or endoscopic invasive tube feeding (ITF - gastroscopy/jejunostomy/stent) is a commonly employed strategy to maintain nutritional support however it can cause significant morbidity in its own right.
  • We sought to determine if a strategy of careful dietary counseling and appropriately-timed neoadjuvant chemotherapy can obviate the need for ITF.
  • METHODS: Pts undergoing neoadjuvant chemotherapy (TAX/CDDP/5FU Q3 weeks x3) for esophageal or GEJ adenocarcinoma at a single institution from 3/07-7/08 were identified from a prospective database.
  • All received dietary counseling and were closely monitored for signs/ symptoms of malnutrition with serial (baseline, after 1<sup>st</sup> cycle, pre-surgery) Body Mass Index (BMI), albumin, dysphagia scores (0 best - 4 worse), and quality of life (FACT-E).
  • We assessed the response of dysphagia and nutritional status to neoadjuvant treatment and the need for ITF.
  • Data presented as median (range) or mean (±SD), paired t-test or Wilcoxon signed ranks test determined significance.
  • RESULTS: 25 pts received neoadjuvant chemotherapy and significant dysphagia (score 2-4) was found in 14.
  • Dysphagia scores improved in all 14 (all results in Table 1 ), and 10/13 improved after the first cycle.
  • No patient required ITF.
  • QoL as assessed by the FACT-E improved in 13/14 patients.
  • A small decrease in BMI was noted, however serum albumin did not significantly decrease.
  • CONCLUSIONS: Appropriately timed neoadjuvant chemotherapy with a highly effective regimen rapidly restores normal swallowing, maintains nutritional status, and obviates the need for ITF in patients with significant dysphagia from esophageal adenocarcinoma.
  • [Table: see text] No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963863.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Casali PG, Stacchiotti S, Palassini E, Marrari A, Negri T, Morosi C, Messina A, Pastorino U, Gronchi A, Pilotti S: Evaluation of the antitumor activity of sunitinib malate (SM) in solitary fibrous tumor (SFT). J Clin Oncol; 2009 May 20;27(15_suppl):10571

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RTK biochemical analysis was performed in 3 patients of this series, in addition to a group of other patients with malignant SFT whose cryopreserved material was available.
  • RESULTS: Between 3 weeks and 3 months, 4 in 5 patients had a tumor response according to Choi's criteria (all with RECIST stable disease) .
  • In two, surgery of residual disease is planned, and downstream RTK signaling analysis will be performed on the specimen.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963778.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Wiechmann L, Jacks L, Patil S, Stempel M, Morrow M: Impact of molecular subtype on presenting characteristics of T1a,b tumors. J Clin Oncol; 2009 May 20;27(15_suppl):11111

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients overexpressing HER2 were significantly younger, had more nodal involvement, multicentric/multifocal (Multi) disease, extensive intraductal component (EIC), and lymphovascular invasion (LVI) (all p<0.0001).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963488.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Nakayama H, Kato Y, Tsuboi M, Okumura S, Daisaki H, Uehara H, Adachi S, Yoshimura M, Okada M: Value of FDG-PET/CT findings revised using an anthropomorphic body phantom for the evaluation of tumor malignancy grade in small-sized lung adenocarcinomas: A multicenter study. J Clin Oncol; 2009 May 20;27(15_suppl):7573

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 7573 Background: The malignant behavior of small lung adenocarinomas (AD), which have been detected with increasing frequency recently, has not yet been clearly evaluated, and an understanding of this biological characteristic is vital for selecting the appropriate therapeutic strategy.
  • RESULTS: Examination of tumor aggressiveness based on the presence of lymphatic, vascular and pleural invasion, and of nodal metastasis, showed that maxSUV, BAC ratio, TDR, and GGO ratio, in the order, can reflect the malignancy grade.
  • MaxSUV and BAC ratio were also valuable prognostic predictors of the disease-free survival.
  • CONCLUSIONS: A higher maxSUV reflects an aggressive malignant behavior of cT1N0M0 ADs, independently of BAC component.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963381.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Di Lorenzo G, De Placido S, Cartenì G, Autorino R, Gonnella A, Rizzo M, Perdona S, Ricevuto E, Aieta M, Ewer M: Cardiovascular toxicity follwing sunitinib therapy in metastatic renal cell cancer: A multicenter analysis. J Clin Oncol; 2009 May 20;27(15_suppl):e16051

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiovascular toxicity follwing sunitinib therapy in metastatic renal cell cancer: A multicenter analysis.
  • We reviewed cardiac adverse events in patients with metastatic renal cell carcinoma (RCC) who underwent treatment with this agent.
  • Among these 17 patients, 12 (70.6%) also experienced left-ventricular systolic (LVEF) dysfunction; in all, 33 of the 175 patients (18.9%) developed some degree of cardiac abnormality, of which 12 were of classified as grade 3 LVEF dysfunction and/or congestive heart failure (CHF) (6.9%).
  • A significant univariate association for predictors of CHF were history of hypertension (p=0.008), history of coronary heart disease (p=0.0005) and prior treatment with an angiotensin converting enzyme inhibitor (ACE) (p= 0.04).
  • Multivariate analysis suggested that a history of coronary artery disease (OR 18, 95% CI, 4-160 p 0.005) and hypertension (OR 3, 95% CI, 1.5-80 p 0.04) were the only significant independent predictors of CHF.
  • CONCLUSIONS: Patients undergoing sunitinib, especially those with a previous history of hypertension and coronary heart disease, are at increased risk for cardiovascular events and should be monitored for exacerbations of their hypertension and for evidence of LVEF dysfunction during treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963002.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Armstrong GT, Pan Z, Ness K, Srivastava D, Robison LL: Temporal trends in cause-specific late mortality among five-year survivors of childhood cancer. J Clin Oncol; 2009 May 20;27(15_suppl):10004

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cause-specific mortality was categorized as death from recurrence/progression of primary disease, external causes, and non-recurrence/non-external causes (Non-Recur/Ext) (i.e., deaths from health conditions including sequelae of cancer therapy).
  • CONCLUSIONS: All-cause late mortality has improved with more recent eras, attributable to reduced rates of mortality from progression of primary disease (i.e., durable remission).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962548.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Papayannidis C, Iacobucci I, Soverini S, Paolini S, Cilloni D, Messa F, Pane F, Ottaviani E, Baccarani M, Martinelli G: Innovative phase I study of concomitant and consecutive treatment with dasatinib and MK-0457 in refractory Ph+ CML and ALL patients. J Clin Oncol; 2009 May 20;27(15_suppl):7080

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The third patient, in progression disease, received the 5 days MK-0457 schedule.
  • After one cycle of MK-0457, a complete recovery of the pulmonary disease and a complete hematologic response were obtained.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961473.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Christy CJ, Rishi M, Schwartz J, Grube BJ, Bossuyt V, Philpotts L, DiGiovanna MP, Tavassoli F, Lannin DR: Association between HER2/neu overexpression and calcifications in breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):579

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between HER2/neu overexpression and calcifications in breast cancer.
  • : 579 Background: HER-2/neu overexpression is an important parameter that influences prognosis and treatment for breast cancer.
  • The purpose of this study is to explore the relationship between HER-2/neu overexpression and calcifications identified by either mammographic imaging or histologic examination.
  • METHODS: A retrospective review of the prospectively collected database was performed to evaluate the mammographic and histologic characteristics of all cases of invasive breast cancers diagnosed between 2003 and 2008.
  • HER-2/neu positivity was defined as either overexpression by FISH analysis or 3+ staining on immunohistochemistry.
  • RESULTS: Of 502 invasive cancers, 165 (33%) had calcifications on mammography and 337 (67%) did not.
  • HER-2/neu positivity was found in 63 (38%) of the calcification cases and 40 (12%) of the non-calcified cases (p < 0.001).
  • This association persisted across all age groups and races and was independent of tumor size, nodal status, or hormone receptor status.
  • Calcifications seen histologically also correlated with HER-2/neu overexpression, but the relationship was more complex.
  • Among 155 cases with histologic calcifications seen within a ductal intraepithelial neoplasia (DIN) component, there were 45 (29%) that were HER-2/neu positive, compared with 67/414 (16%) that did not have calcifications within DIN (p < 0.001).
  • If the calcifications were only within invasive tumor, the rate of HER-2/neu overexpression was less, 9/63 (14%).
  • Univariate analysis demonstrated that tumor grade, necrosis, lymphovascular invasion and hormone receptor negativity were significantly associated with HER-2/neu overexpression (all p < 0.01).
  • Multivariate logistic regression showed only the following factors to be significantly associated with HER-2/neu overexpression: grade of invasive tumor, presence of necrosis, progesterone receptor negativity in either the invasive or the in situ component, and mammographic calcifications.
  • CONCLUSIONS: Recognition of the strong association between HER-2/neu overexpression and mammographic calcifications may have clinical usefulness and could lead to a better understanding of the underlying tumor biology of this important tumor marker.
  • [Table: see text].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960749.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Holmström R: Beyond black and white. Nurs Stand; 2010 Oct 13;25(6):62-63

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Beyond black and white.
  • : 'Assumptions based on a patient's appearance may well have an effect on clinical judgements - but that is not all,' says RCN diversity and equalities co-ordinator Wendy Irwin.
  • 'If patients do not feel understood at a time when they are at their most vulnerable, that is an important issue of dignity and one that nurses specifically should keep in mind. '

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28029951.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


36. Smith MA, Morton CL, Carol H, Gorlick RG, Kang MH, Keir ST, Kolb EA, Lock RB, Maris JM, Houghton PJ: Pediatric Preclinical Testing Program (PPTP) testing of the CENP-E inhibitor GSK923295A. J Clin Oncol; 2009 May 20;27(15_suppl):10015

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The PPTP includes a molecularly characterized in vitro panel of cell lines (n = 27) and in vivo panel of xenografts (n = 60) representing most of the common types of childhood solid tumors and childhood acute lymphoblastic leukemia (ALL).
  • RESULTS: GSK923295A demonstrated potent in vitro activity against the PPTP cell line panel with a median IC50 of 27 nM (range 12 nM to > 10 μM).
  • For the neuroblastoma panel, the best response was progressive disease (PD) with growth delay compared to controls (PD2 response), which was observed in 5 of 6 xenografts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962529.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Epenetos AA, Kousparou C, Stylianou S: Inhibition of Notch and tumor regression. J Clin Oncol; 2009 May 20;27(15_suppl):e14623

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e14623 Background: Notch signaling is an evolutionary-conserved pathway in vertebrates and invertebrates which is involved many developmental processes, including cell fate decisions, apoptosis, proliferation, and stem-cell self renewal.
  • Increasing evidence suggests that the Notch signaling pathway is frequently up regulated in many forms of cancer including acute T-cell lymphoblastic leukemia, cervical, prostate, lung, breast and others.
  • RESULTS: Our data show that ANTP/DN MAML fusion protein, TR4 contains signals for proper cell targeting, internalization and nuclear transport.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964214.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. von Mehren M, Chu Q, Alcindor T, Townsley C, Thallury S, MacAlpine K, Wright JJ, Oza A: Early results of a PMH Phase II Consortium trial of AZD0530 in advanced soft tissue sarcoma (STS). J Clin Oncol; 2009 May 20;27(15_suppl):10579

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Src kinases play a role in tumor cell migration, invasion and metastasis as well as being part of the signaling cascade for angiogenesis and growth factors.
  • METHODS: The study utilized a Simon Two stage design with the primary endpoint be objective tumor response + prolonged stable disease rate (defined as partial/complete response by RECIST, or stable disease >4 months).
  • Patients with measurable advanced STS with up to one prior chemotherapy for metastatic disease were eligible for study participation following informed consent.
  • Nine discontinued therapy for progressive disease, 2 for toxicity and 1 patient request.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963760.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Fuchs E, Köstler W, Horvath R, Hudelist G, Kubista E, Attems J, Zielinski C, Singer CF: Use of the ErbB2/CEP17 ratio to predict prognosis and response to trastuzumab-based therapy in the metastatic breast cancer setting. J Clin Oncol; 2009 May 20;27(15_suppl):11110

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Significant differences in complete response (B/C: 16.9% vs C:44.4%), partial response (B/C: 20.2% vs. C: 33.3%) and progressive disease (B/C: 27% vs. 11.1%) were noted.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963491.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Ayllon J, Banu E, Leviel F, Houillier P, Medioni J, Barrascout E, Oudard S, Maruani G: Bone markers in prostate cancer (PC) patients: Biologic criteria to identify patients at risk of developing distant metastases. J Clin Oncol; 2009 May 20;27(15_suppl):e16069

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e16069 Background: Currently, there are no specific serum and/or urinary bone markers able to accurately identify PC patients with hormone-refractory disease and/or those with distant metastases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963065.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Quevedo F, Ashdown ML, Suman VJ, Robinson A, Kottschade LA, Kaur JS, Creagan ET, McWilliams RR, Markovic SN: Possible therapeutic reversal of immune suppression in patients with metastatic melanoma by timed delivery of temozolomide chemotherapy: A pilot study. J Clin Oncol; 2009 May 20;27(15_suppl):e20013

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: All 12 patients (median age 61; 4 female; 7 with M1c disease) exhibited oscillating CRP levels with an average periodicity of 7.8 days.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962562.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Herzog TJ, Vermorken JB, Pujade-Lauraine E, Li J, Bayever E, Gomez J, Yovine A, Monk BJ: Correlation of CA-125 and RECIST evaluation in recurrent ovarian cancer (ROC): Results from a randomized phase III study of trabectedin (T) with pegylated liposomal doxorubicin (PLD) versus PLD alone. J Clin Oncol; 2009 May 20;27(15_suppl):5550

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of CA-125 and RECIST evaluation in recurrent ovarian cancer (ROC): Results from a randomized phase III study of trabectedin (T) with pegylated liposomal doxorubicin (PLD) versus PLD alone.
  • : 5550 Background: OVA-301, an open-label, multicenter, randomized phase III study comparing the combination of T and PLD to PLD alone in 672 ovarian cancer patients, showed significant prolongation in Progression-Free Survival (PFS) and higher Objective Response (OR) in the combination arm (T-PLD) by three separate assessments, investigator assessment (IA), independent radiology (IR) and oncology review (IO).
  • The purpose of this analysis is to examine:.
  • 1) the impact of early changes in CA-125 over the subsequent best OR by RECIST;.
  • 2) the concordance between best OR determined by CA-125 and RECIST;.
  • 3) the value of CA-125 to predict radiological response.
  • METHODS: Tumor assessments by imaging and CA-125 were performed at baseline, and every 8 weeks during study in both arms.
  • Radiological tumor assessment, regardless of CA-125 changes, determined the study conduct.
  • Early CA-125 changes were those assessed at the first and second evaluation.
  • Analyses were based on "all randomized patients."
  • RESULTS: Response rate by RECIST (IR)/CA-125 was 28%/48% for T-PLD vs. 19%/33% for PLD.
  • The association between CA-125 and RECIST response was stronger for IA relative to IR/IO, with 79% concordance for both arms, 65% overall positive predictive value (PPV) and 89% negative predictive value (NPV) for IA and 74%/75% concordance, 46%/49% PPV and 93%/92% NPV for IR/IO.
  • Early CA-125 changes were assessed in 514 patients.
  • Early ≥25% CA-125 decreases in the first/second evaluation occurred in 85%/95% of RECIST responders in the T-PLD arm and in 81/82% responders treated with PLD.
  • CONCLUSIONS: The predictive value of CA-125 response was high and similar in both arms.
  • The addition of T to PLD resulted in superior efficacy in this patient population as assessed by IA, IR and IO, with a favorable trend for CA-125 response assessment.
  • RECIST response was preceded by a significant CA-125 decrease in a high proportion of patients.
  • [Table: see text].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962544.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Murakami F, Ogawa N, Yamazaki A, Sakurai S, Ishiya T, Katase K, Shimizu Y, Tanada S: Evaluation of preoperative positron emission tomography with computed tomography (PET-CT) for detecting lymph node metastasis in gynecologic carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):5593

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The sensitivity of squamous cell carcinoma (SCC) were 35.7%, that of adenocarcinoma were 8.1%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962404.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Escofet X, Twine C, Roberts A, Dave B, Rawlinson C, Chan D, Crosby T, Robinson M, Lewis W: Prognostic significance of endoluminal ultrasound defined tumor volume (EDTV) in patients diagnosed with esophageal cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15519

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: One hundred and seventy-four consecutive patients (median age 64y, 128 m) underwent both CT and specialist EUS, and the maximum potential tumour cylinder volume (EDTV) was calculated using the formula πr<sup>2</sup>L (cylinder volume), where r = tumour thickness (cm) and L = total length of disease, including the position and level of both the primary tumour and proximal and distal lymph nodes (cm).
  • RESULTS: Survival was related to EUS T (p=0.013), EUS N (p=0.001), EUS M1a stage (p=0.004), EUS disease length (p=0.001), and EDTV (all patients <25cm<sup>3</sup>, p=0.001, surgical patients <40cm<sup>3</sup>, p=0.036).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962290.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Ward to board leadership. Nurs Stand; 2009 Oct 14;24(6):24-25

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ward to board leadership.
  • : Nursing directors are supposed to ensure that clinical quality features frequently on the agendas of NHS board meetings and is monitored at board level.
  • On the face of it, nurse directors are ideally placed to promote clinical quality.
  • After all, nurses and midwives are seen as key to providing quality care.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28080695.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


46. Pay cut after 'best year'? Nurs Stand; 2006 Nov 01;21(8):1

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pay cut after 'best year'?
  • : When governments boast about how well the health service is performing under their stewardship - usually the number of patients treated and how quickly - they are really describing the achievements of staff in hospitals and the community.
  • After all, no minister has ever actually walked into a treatment centre or a patient's home and delivered care themselves.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28010483.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


47. Terms of endearment. Nurs Stand; 2008 Dec 03;23(13):13

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Terms of endearment.
  • : Some nurses address their older patients as 'love' or 'dearie' simply as a term of endearment.
  • Others say it because they have forgotten the names of their patients.
  • But what is clear from new Nursing and Midwifery Council (NMC) guidance is that no nurse should be using those terms at all.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28010406.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


48. Lu Q, Zhao A, Shen L: Preoperative transcatheter arterial chemoembolization (TACE) and chemotherapy for hepatic colorectal metastases: Impact on hepatic histology and postoperative outcome. J Clin Oncol; 2009 May 20;27(15_suppl):e15090

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative transcatheter arterial chemoembolization (TACE) and chemotherapy for hepatic colorectal metastases: Impact on hepatic histology and postoperative outcome.
  • : e15090 Background: The objective was to evaluate the effect of preoperative administration of TACE and chemotherapy on hepatic injury and on postoperative outcome in patients with colorectal liver metastases (CRM) Methods: Seventy seven patients underwent hepatic resection for CRM between January 1999 and December 2007 were evaluated.
  • Pathologic review of the non-tumorous liver was performed using established criteria for steatosis, steatohepatitis, and sinusoidal dilation.
  • The effect of two different treatment and hepatotoxicity on postoperative outcome was analyzed.
  • RESULTS: 40 patients (51.9%) received no preoperative treatment, where 27 patients (35.0%) received preoperative chemotherapy, 10 patients (12.9%) performed TACE before resection.
  • The median duration of TACE group was 4.5 months (range, 1-6 months), where the median duration of chemotherapy group was 5 cycles (range, 2-9 cycles).
  • Chemotherapy regimen consisted of oxalipaltin plus FU (29.9%), or irinotecan plus FU (5.2%).
  • On pathologic analysis, 36 patients (46.7%) had steatosis, 24 (31.1%) had sinusoidal dilation, and 8 (10.3%) had steatohepatitis.
  • TACE was associated with steatosis, steatohepatosis and postoperative complication, when compared with no chemotherapy (all p<0.05).Among chemotherapy group,Oxaliplatin was associated with steatohepatitis compared with no preoperative treatment (13.0% v 0%, respectively; p<0.05).
  • Irinotecan was associated with steatohepatitis compared with no preoperative treatment (50% v 0%, respectively; p=0.0006).
  • Patients with preoperative chemotherapy had increased steatohepatitis compared with no treatment group (18.5% v 0%, respectively, p=0.0008), the postoperative morbility rate in preoperative chemotherapy (25.9%) was double that of the no-chemotherapy (12.5%), but this difference was not statistically significant (p=0.20).
  • Preoperative chemotherapy was also not associated with 90-day mortality.
  • CONCLUSIONS: Preoperative TACE treatment may cause pathological liver injury, and increase postoperative morbility after hepatic surgery.
  • The standard preoperative chemotherapy regimen with Oxaliplatin or Irinotecan may increase steatohepatis.
  • No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964609.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Wulfing C, Herrmann E, Trojan L, Schrader A, Becker F, Stähler M, Haferkamp A, Legal W, Brenner W, Hartmann A, German Papillary Renal Cancer Study Group: Independent validation of the 2002 UICC TNM staging system for papillary renal cell carcinoma in a multicenter cohort. J Clin Oncol; 2009 May 20;27(15_suppl):5092

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Independent validation of the 2002 UICC TNM staging system for papillary renal cell carcinoma in a multicenter cohort.
  • : 5092 Background: Papillary renal cell carcinoma (pRCC) is the second most malignant histologic subtype in nephrectomy specimens.
  • Synchronous distant metastases in the entire group occurred in 58 (8.7%) patients and 69 (11.2%) others developed metastatic disease during follow-up.
  • Patients with ≥pT3 were at high risk for metastases (50.6%), while metastatic disease associated with ≤pT2 tumors occurred in 7.8% (p < 0.0001).
  • Once metastatic disease was present, prognosis was poor (5-year CSS: 7.2%).
  • Clinical and radiologic follow-ups should be offered in frequent intervals to patients with venous thrombus and/or locally advanced disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964296.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Nadeem A, Wanebo H, Shrayer D, Hazelwood S, Resnick M: Effect of the apoptosis signal ceramide (C6) on antitumor activity of chemotherapeutic agents in SCID mice. J Clin Oncol; 2009 May 20;27(15_suppl):e14642

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of the apoptosis signal ceramide (C6) on antitumor activity of chemotherapeutic agents in SCID mice.
  • : e14642 Introduction: The ceramides are a major signaling pathway for apoptosis in cells undergoing stress or exposure to chemotherapy.
  • We have demonstrated synergistic anti-tumor effects of combining C6 ceramide with paclitaxel, doxorubicin and cisplatin and are currently addressing the question; does C6 augment activity of all the major classes of drugs?
  • Backround: Currently the in vivo anti-tumor effects of C6 with oxaliplatin and Gemcitabine.
  • METHODS: Invivo experiments SCID/Beige/Taconic male mice inoculated S.C. with 2X106 L3.6 pancreatic cells were treated 4 days post tumor implant with trice weekly (3x/wk) intraperitoneal (IP) injections of paclitaxel (P) 3.0 m/kg, oxaliplatin (OX) 2.5 mg/kg, cisplatin (CP) 2.5 mg/kg, Gemcitabine (Gem) 10 mg/kg with/without ceramide 10 mg/kg.
  • Mice were observed for 6 weeks and were autopsied when near death. (All controls died by 3<sup>rd</sup> week).
  • Maximum tumor volume, tumor weight; body weight and survival were recorded.
  • RESULTS: Combination with C6 ceramide augmented the tumor reduction obtained by chemotherapy alone by 57% (while preserving body weight), and increased 6 week survival from 0% (Chemotherapy alone) to 60% with combined therapy.
  • Mean survival was increased from 25 to 37 days.
  • Although short term immunohistochemical studies suggested enhanced apoptosis and increased caspase 3 production by ceramide combinations it may actually be independent of capase activation and mitochondrial activation.
  • CONCLUSIONS: Combination therapy with the apoptotic signal C6 ceramide significantly enhanced the anti-tumor effects of the anti microtubule, alkylating Paclitaxel a DNA interculating antibiotic (doxorubicin) the alkylating/DNA adducting agents (cisplatin, oxaliplatin) and an anti metabolite (gemcitabine) suggesting generation of broad based apoptotic signals which interact with major cancer drug classes (tested).
  • No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964231.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Pavoni-Ferreira PC, Petrilli AS, Alves MT, Jesus-Garcia Filho R, Toledo SR: Angiogenic biomaker study in osteosarcoma. J Clin Oncol; 2009 May 20;27(15_suppl):e21507

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiogenic biomaker study in osteosarcoma.
  • : e21507 Background: This study represents a prospective assessment of angiogenesis genes mRNA expression in tumors and blood from patients treated with pre- and post-operative Brazilian osteosarcoma protocol (GCBTO 2006) that introduce metronomic chemotherapy (anti-angiogenic) in order to try to increase survival of osteosarcoma patients.
  • METHODS: Tumor samples from 27 patients were analyzed before and after chemotherapy to determine VEGFA, VEGFR1, VEGFR2, PDGFC, SDF1 and TSP1 genes expression profile by Quantitative Real Time PCR.
  • Also, blood samples of these patients were investigated pre- and post-chemotherapy and at the end of high-dose chemotherapy trying to evaluate potential for proangiogenic factors and antiangiogenic factor (TSP1) which could be used to monitor treatment activity.
  • RESULTS: Of all six genes studied pre- and post- chemotherapy, in tumor samples, only SDF1 and VEGFR2 were underexpressed.
  • SDF1 gene has the lowest expression at all.
  • In tumor samples, TSP1 and VEGFA expression was higher than SDF1, VEGFR2 and PDGFC expression in biopsies and surgeries (P=0.001).
  • VEGFR1 expression was higher than VEGFR2 expression (P=0.001).
  • PDGFC and VEGFR1 overexpression were associated with necrosis grade I and II (Huvos score) (P=0.005).
  • VEGFA and TSP1 were overexpressed in 96% and 92% of surgery samples, respectively.
  • In blood samples from biopsy, surgery and end of treatment there were no statistically significant changes in the marker genes expression.
  • CONCLUSIONS: The study suggests an association between PDGFC and VEGFR1 overexpression and lower grade necrosis.
  • TSP1 and VEGFA were the most expressed genes in all tumor samples but TSP1 was lower than VEGFA in biopsies and VEGFA was lower than TSP1 in surgery (P=0.001).
  • Although VEGFR2 is the primary receptor of VEGF, VEGFR1 was the most expressed VEGF receptor.
  • No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963397.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Merrell RT, Lachance DH, Anderson SK: Seizures in patients with glioma treated with phenytoin and levetiracetam. J Clin Oncol; 2009 May 20;27(15_suppl):e13020

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Seizures in patients with glioma treated with phenytoin and levetiracetam.
  • : e13020 Background: Seizures are common in patients with glioma.
  • Phenytoin, traditionally used for these patients, can be associated with intolerable side effects and potentially alters the metabolism of chemotherapeutic agents.
  • Levetiracetam has more favorable pharmacokinetics facilitating ease of use with fewer side effects and is nonenzyme inducing.
  • We compare seizure outcomes and side effects in patients with glioma treated with phenytoin and levetiracetam monotherapy.
  • METHODS: Retrospective analysis of consecutive patients with glioma.
  • Subjects had at least one clinical seizure and had to be followed for 6 months.
  • Seizure outcomes and side effects were compared between cohorts treated with phenytoin or levetiracetam.
  • Seizure outcomes were measured by time to second seizure and seizure frequency.
  • RESULTS: 76 patients (34 female) with pathologically proven glioma and seizures were identified, 25 treated with phenytoin and 51 with levetiracetam.
  • 64% had grade 4 astrocytoma.
  • There was no difference in seizure outcome between the phenytoin and levetiracetam groups when comparing time to second seizure (p = 0.584), second seizure rates (p = 0.462), and average seizures per month (p = 0.776).
  • When adjusting for age, gender, type of seizure, type of glioma, and dosage using univariate and multivariate models there were no differences between the treatment groups and none of these covariates were statistically significant for explaining the second seizure rates between treatment groups (all p values >0.05).
  • The incidence of side effects in the levetiracetam group was 5.9% versus 20% in the phenytoin group (p = 0.106).
  • Additionally, 36.0% of the patients in the phenytoin group had dose adjustments not related to breakthrough seizures compared to only 9.8% in the levetiracetam group (p = 0.010).
  • CONCLUSIONS: In this study, glioma patients treated with levetiracetam had similar seizure control as patients treated with phenytoin.
  • Patients treated with levetiracetam experienced fewer side effects and required fewer non seizure related dose adjustments than patients treated with phenytoin.
  • Levetiracetam is a safe, effective, and preferred alternative for seizure management in patients with glioma.
  • No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962817.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Pavlakis N, Hirsh V, Reck M, Wu Y, Dansin E: MO19390 (SAiL): Incidence of thromboembolic events and congestive heart failure with first-line bevacizumab (Bv)-based therapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):e19003

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MO19390 (SAiL): Incidence of thromboembolic events and congestive heart failure with first-line bevacizumab (Bv)-based therapy in advanced non-small cell lung cancer (NSCLC).
  • METHODS: Key eligibility criteria were untreated locally advanced, metastatic or recurrent non-squamous NSCLC, ECOG PS 0-2, tumor not abutting major blood vessels, no uncontrolled HTN (systolic >150mmHg and/or diastolic >100mmHg) or active cardiovascular disease at baseline.
  • Non-progressors proceeded to receive Bv until disease progression.
  • Pts (%) were: male 60.1; stage IIIB/IV 19.5/80.5 (no data for 3 pts); adenocarcinoma/large cell/other 85.8/7.1/7.1; ECOG PS 0/1/2 38.1/56.1/5.8.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962518.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Yeo W, Goh B, Le Tourneau C, Green SR, Chiao JH, Siu LL: A phase II randomized study of oral seliciclib in patients with previously treated nasopharyngeal carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):6026

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Eligible patients must be ≥18 years with previously treated NPC or other incurable solid tumors; must have measurable disease according to RECIST, ECOG 0-1, and adequate bone marrow, hepatic and renal function.
  • Majority of stable disease occurred in NPC patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962434.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Gilbert J, Lee J, Argiris A, Feldman L, Haigentz M, Burtness B, Forastiere A, Eastern Cooperative Oncology Group: Phase II randomized trial of bortezomib (B) plus irinotecan (I) or B with addition of I at progression in recurrent (R) or metastatic (M) squamous cell carcinoma of the head and neck (SCCHN) (E1304): A trial of the Eastern Cooperative Oncology Group. J Clin Oncol; 2009 May 20;27(15_suppl):6020

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II randomized trial of bortezomib (B) plus irinotecan (I) or B with addition of I at progression in recurrent (R) or metastatic (M) squamous cell carcinoma of the head and neck (SCCHN) (E1304): A trial of the Eastern Cooperative Oncology Group.
  • : 6020 Background: B, inhibits activation of NF- κβ and inhibits growth of SCCHN cell lines.
  • To date, RR low but prolonged stable disease noted in some pts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962416.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Wang XS, Williams LA, Johnson VE, Mao L, Krishnan S, Liao Z, Mobley G, Cleeland CS: Association of sTNF-R1 and the development of treatment-related symptoms in patients undergoing concurrent chemoradiation therapy for colorectal or esophageal cancer. J Clin Oncol; 2009 May 20;27(15_suppl):3041

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Serum samples were tested weekly during therapy for changes in concentration levels of inflammatory cytokines (interleukin [IL]-6, IL-8, IL-10, IL-1 receptor antagonist [IL-1RA], vascular endothelial growth factor [VEGF], and soluble tumor necrosis factor receptor type 1 [sTNF-R1]) via enzyme-linked immunosorbent assay (ELISA).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961980.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Garcia-Manero G, Luger S, Venugopal P, Maness L, Wetzler M, Coutre S, Stock W, Borthakur G, Chiao J, Kantarjian H: A randomized phase II study of sapacitabine, an oral nucleoside analogue, in elderly patients with AML previously untreated or in first relapse or previously treated MDS. J Clin Oncol; 2009 May 20;27(15_suppl):7021

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 7021 Background: Sapacitabine is a novel nucleoside analogue with a unique ability to cause irreparable single-strand DNA breaks and induce G2 cell cycle arrest.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961383.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Grimley PM, Matsuno R, Anderson WF: Population profiles of extra-ovarian and ovarian serous adenocarcinomas: Comparisons with grade stratification. J Clin Oncol; 2009 May 20;27(15_suppl):e16506

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Incidence rates (IR) stratified by grade were compared by year or age of diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960765.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Have a look at the other side of the work/life balance. Nurs Stand; 2007 Aug 01;21(47):32

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Have a look at the other side of the work/life balance.
  • : Has nursing become the most selfish profession of all?
  • We constantly moan about night shifts, how staff shortages and deficits are detrimental to quality patient care and nursing intervention, and how this limits our ability to provide the highest standards of nursing.
  • On the other hand, I cannot help but notice how we seem to forget to look after each other when it comes to shift allocation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28001636.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


60. Sampat KR, Garcia-Gutierrez V, Rossi A, Pierce S, Cortes J, Kantarjian H, Garcia-Manero G: Prevalence and therapeutic relationships of pericardial effusions in patients with leukemia. J Clin Oncol; 2009 May 20;27(15_suppl):7067

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence and therapeutic relationships of pericardial effusions in patients with leukemia.
  • : 7067 Background: Little is known regarding the prevalence and natural history of pericardial disease in patients with leukemia.
  • To study this issue, we retrospectively analyzed a large cohort of patients with leukemia, who were evaluated at MD Anderson Cancer Center (MDACC), to determine the prevalence, timing, and characteristics of PEf in leukemia.
  • METHODS: We reviewed 3,327 patients with acute myeloid leukemia (AML, N = 1,809, 54%), acute lymphocytic leukemia (ALL, N = 494, 15%), or myelodysplastic syndrome (MDS, N =1,024, 31%), who were seen at MDACC from August 2003 to July 2008.
  • Data regarding diagnosis, timing, effusion size, and prior therapy was collected in the 401 patients (20.2%) that had echocardiographic evidence of PEf.
  • In the 401 total patients with PEf, 22.8%, 25.0%, and 18.4% (p = 0.33) of these effusions were found before treatment in the three disease categories, respectively.
  • The rest occurred after some form of chemotherapy, accounting for 77.2%, 75.0%, and 81.6% (p = 0.73) of the total PEf by disease, respectively.
  • CONCLUSIONS: PEf are relatively common in patients with leukemia at initial presentation and are usually asymptomatic.
  • Their incidence increases with therapy administration although it appears that this is not a process related to specific classes of treatment or type of leukemia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961462.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Reservists seek more support from managers and staff. Nurs Stand; 2008 Oct 22;23(7):12-13

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reservists seek more support from managers and staff.
  • : Being a reservist in the Royal Navy is not all about spending weekends on ships or training for combat.
  • By joining the 1,600 members of the NHS in the UK's reserve forces, nurses can gain key clinical and leadership skills, as well as taking part in life-saving humanitarian missions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28006359.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


62. The biological basis of nursing - cancer William T Blows The biological basis of nursing - cancer Routledge 360pp £;20.99 0 415 32746 6 0415327466 [Formula: see text]. Nurs Stand; 2005 Dec 07;20(13):36

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The biological basis of nursing - cancer William T Blows The biological basis of nursing - cancer Routledge 360pp £;20.99 0 415 32746 6 0415327466 [Formula: see text].
  • : William Blows begins the introduction to this book by stating: 'Life is all about biology.
  • ' He believes most of us are guilty of seeing biology as just a subject, rather than an actual living and happening event around us and driving us.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28001787.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


63. Newnham D: Outsidein - the euro health insurance card expires. David Newnham thinks he knows why. Nurs Stand; 2009 Apr 08;23(31):26-27

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outsidein - the euro health insurance card expires. David Newnham thinks he knows why.
  • : Shock, horror, read all about it - millions of European Health Insurance Cards (EHICs) are about to expire.
  • Feckless Brits face Euro- holiday hell.
  • Department of Health (DH) calls in TV doctor.
  • Honestly, anyone would think avian flu had suddenly landed at Gatwick.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27996519.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


64. Bates J: Quality is key. Nurs Stand; 2009 Apr 29;23(34):27

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality is key.
  • : Do you have targets in your life?
  • I suppose we all do.
  • Mine are generally domestic.
  • For example, by next Christmas I will have caught up with the ironing.
  • It is overambitious, I know, and unlikely to happen, but if I do not at least have a target then there is no hope at all.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27991067.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


65. Bloomfield CD: Importance of genetic heterogeneity in curing adult acute leukemia (AL). J Clin Oncol; 2009 May 20;27(15_suppl):s1

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Importance of genetic heterogeneity in curing adult acute leukemia (AL).
  • Publication of the French-American-British classification 34 years ago resulted in acceptance that morphology and cytochemistry separated AL into two different diseases, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), that required separate treatment.
  • The most striking example of increased curability of AL is acute promyelocytic leukemia, in which targeted therapy combined with chemotherapy has increased survival from a 2-week median to an 80% cure rate.
  • Among adult de novo AML 40%-45% are cytogenetically normal (CN); the striking molecular heterogeneity of CN-AML is now being recognized and promises to allow individualized approaches that improve substantially upon the current cure rate of 40%.
  • New approaches to studying the leukemia genome and epigenome should improve our understanding of AL heterogeneity, identify new therapeutic targets, and allow the cure of most patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962366.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Khattab TM, Jastaniah WA, Felimban SK, Elemam N, Abdullah K, Ahmed B: How could improvement in the management of T-cell acute lymphoblastic leukemia be achieved? Experience of Princess Nourah Oncology Center, National Guard Hospital, Jeddah, Saudi Arabia. J Clin Oncol; 2009 May 20;27(15_suppl):10048

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] How could improvement in the management of T-cell acute lymphoblastic leukemia be achieved? Experience of Princess Nourah Oncology Center, National Guard Hospital, Jeddah, Saudi Arabia.
  • : 10048 Background: T-cell acute lymphoblastic leukemia (T-ALL) is representing 10-15% of pediatric ALL.
  • Our published data showed that T-ALL phenotype patients fared poorly with 5 year survival of 27% versus 83% for precursor B-ALL (Recent Advances Research Update: 2006, 7; 1, P 51-56).
  • METHODS: Retrospective review of all patients files diagnosed with T-ALL from 1989 until now with data collection including; sex, age, white cell count (WBCs), CNS disease, type of protocol used, length of survival, overall survival, cause of death (toxic, disease).
  • Median WBCs 50,000/Cmm (range: 1.500-619,000/Cmm) and positive CNS at diagnosis 10/52 (20%).
  • Overall survival 27/52 (52%) and 25 pts. died (48%); 15 secondary to disease recurrence (9 on UKALL, 4 BFM, 2 CCG 1961); 4 during induction, 1 fulminant hepatic failure, 1 tumor lysis syndrome, and 4 due to toxicities (mucormycosis, staphylococcal toxic shock syndrome, CMV pneumonia, pseudomonas sepsis).
  • Further risk and response stratification in addition to intensification of therapy for T-cell ALL in our center may prove to be beneficial.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962474.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Dempsey RJ: Neurogenesis in Adults: Maybe You can Teach Old Dogs New Tricks after All! Neurosurgery; 2009 Apr 01;64(4):N12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurogenesis in Adults: Maybe You can Teach Old Dogs New Tricks after All!

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28175563.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Fauzdar A, Mahajan A, Jain D, Mishra M, Raina V: Amplification of RUNX1 gene in two new cases of childhood B-cell precursor acute lymphoblastic leukemia: A case report. J Clin Oncol; 2009 May 20;27(15_suppl):e21000

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amplification of RUNX1 gene in two new cases of childhood B-cell precursor acute lymphoblastic leukemia: A case report.
  • : e21000 Background: Chromosome abnormalities of leukemia cells have important prognostic significance in childhood acute lymphoblastic leukemia (ALL).
  • B-cell precursor acute lymphoblastic leukemia (BCP-ALL) ETV6/RUNX1 (alias TEL/AML1) is most frequent i.e.
  • We report two new cases with Pre B- cell ALL without ETV6/RUNX1 rearrangement, showing amplification of AML1 gene detected by FISH analysis.
  • RESULTS: In first case a 3-year girl with four copies of AML (RUNX1) gene were observed in 95% of the cell with normal two copies of TEL (ETV6) gene in both interphase and metaphase FISH.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960689.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Meyer LH, Zangrando A, Eckhoff SM, Queudeville M, Vendramini E, Basso G, Te Kronnie G, Debatin K: Association of time to leukemia (TTL) in NOD/SCID mice with expression of apoptosis regulators in pediatric ALL. J Clin Oncol; 2009 May 20;27(15_suppl):10042

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of time to leukemia (TTL) in NOD/SCID mice with expression of apoptosis regulators in pediatric ALL.
  • : 10042 Background: Acute lymphoblastic leukemia (ALL) is the most frequent malignant disease in childhood.
  • In a recent study we transplanted pediatric leukemia samples from newly diagnosed BCP-ALL patients into NOD/SCID mice.
  • Time to leukemia (TTL) was analyzed for each patient sample as time from transplant to overt leukemia in the recipients.
  • Patients whose leukemia cells engrafted rapidly showed a clearly inferior relapse free survival in contrast to patient samples with prolonged in vivo growth.
  • METHODS: Gene expression profiles of ALL samples (N = 14) with short versus long TTL in the xenograft model were analyzed using a human whole genome array (Affymetrix U133 Plus 2.0) correlating gene expression values (relative expression) to the time from transplant to manifestation of leukemia in the NOD/SCID mice (TTL, in weeks) by quantitative traits analysis (QTA).
  • Patient samples exhibiting a short time to overt leukemia in the xenotransplant model associated with poor relapse free survival showed down-regulated XAF1 and impaired caspase-3 activation leading to decreased apoptosis of the leukemia cells.
  • CONCLUSIONS: Taken together, we used a novel approach directly correlating gene expression values to time from transplant to overt leukemia (TTL) identifying the apoptosis regulator XAF1 to be associated with poor outcome of patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962468.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Ikawa Y, Sugimoto N, Koizumi S, Yachie A, Saikawa Y: Promoter DNA methylation of CD10 in infant acute lymphoblastic leukemia with MLL/AF4 fusion gene. J Clin Oncol; 2009 May 20;27(15_suppl):10045

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Promoter DNA methylation of CD10 in infant acute lymphoblastic leukemia with MLL/AF4 fusion gene.
  • While CD10 negativity reflects an earlier stage of B-cell development, complete IgH gene rearrangements (VDJ<sub>H</sub>) show more mature IgH status.
  • METHODS: CD10-negative infant ALL with MLL/AF4, CD10-positive infant ALL with germ-line MLL, CD10-positive pre-B ALL cell line, infant AML (M5) with MLL/AF9 and pediatric AML (M2) with AML1/ETO were analyzed for VDJ<sub>H</sub> status and methylation of CD10 gene promoters.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962471.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. What price this pay rise? Nurs Stand; 2007 Mar 07;21(26):1

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] What price this pay rise?
  • : There was outrage when a trust suggested that staff should work a day for free to help its finances.
  • And rightly so.
  • But now it seems the same principle is being applied nationally.
  • That really is the only conclusion to be drawn from the decision to stage your 2007 pay award.
  • After all, an independent review body looked at all the evidence, including ministers' arguments about affordability, and decided that a fair award this year would be 2.5 per cent.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27967387.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


72. The best job of all. Nurs Stand; 2010 Oct 13;25(6):22-23

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The best job of all.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28029950.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Nursing care / ● Campaigns / ● Nurse champion / ● Nurses awards / ● Patient safety / ● RCN
  •  go-up   go-down


73. Bhargava P, Esteves B, Nosov DA, Lipatov ON, Lyulko AA, Anischenko AA, Chacko RT, Lee P, Al-Adhami M, Ryan J: Updated activity and safety results of a phase II randomized discontinuation trial (RDT) of AV-951, a potent and selective VEGFR1, 2, and 3 kinase inhibitor, in patients with renal cell carcinoma (RCC). J Clin Oncol; 2009 May 20;27(15_suppl):5032

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Updated activity and safety results of a phase II randomized discontinuation trial (RDT) of AV-951, a potent and selective VEGFR1, 2, and 3 kinase inhibitor, in patients with renal cell carcinoma (RCC).
  • 53% pts were treatement naïve, 72% had undergone nephrectomy and 83% had RCC with clear cell component.
  • With a median duration of treatment of 5 mo (range 0-12 mo), the investigator assessed ORR (CR+PR) is 27.2% (30% in clear cell RCC), SD 60.5% and Disease Control Rate (CR/PR + SD) 88%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962939.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Te Loo DM, van Schie RM, Hoogerbrugge PM: Effect of azole antifungal therapy on vincristine toxicity in childhood acute lymphoblastic leukemia. J Clin Oncol; 2009 May 20;27(15_suppl):10049

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of azole antifungal therapy on vincristine toxicity in childhood acute lymphoblastic leukemia.
  • : 10049 Background: Vincristine is one of the corner stitches in the treatment of children with acute lymphoblastic leukemia (ALL).
  • METHODS: In total, twenty pediatric patients with de novo ALL were included in this study.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962456.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Yeh C, Ma W, Kantarjian H, Zhang ZJ, Cortes J, Albitar M: BCR-ABL truncation due to premature translation termination as a mechanism of resistance to kinase inhibitors. J Clin Oncol; 2009 May 20;27(15_suppl):7028

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 7028 Background: The major mechanism underlying imatinib resistance in patients with chronic myeloid leukemia (CML) is clonal expansion of leukemic cells with point mutations in the BCR-ABL tyrosine kinase.
  • We describe three novel ABL premature termination mutations leading to BCR-ABL truncation in leukemia patients with multidrug (imatinib/nilotinib/dasatinib) resistance.
  • HL60 cells (a Ph-negative myeloid leukemia cell line) and peripheral blood of healthy subjects were used as negative controls; a human CML cell line (K562) was used as a positive control.
  • RESULTS: We identified an exon 7 deletion in three CML patients, a 4-nt insertion (908insCAGG) near the exon 5/6 junction in one CML case, and an exon 6 point mutation (997C>T) in one patient with acute lymphoblastic leukemia (ALL).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961401.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Lipshultz SE, Scully RE, Lipsitz SR, Sallan SE, Silverman LB, Miller TL, Orav EJ, Colan SD: Gender differences in long-term dexrazoxane cardioprotection in doxorubicin-treated children with acute lymphoblastic leukemia. J Clin Oncol; 2009 May 20;27(15_suppl):10005

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gender differences in long-term dexrazoxane cardioprotection in doxorubicin-treated children with acute lymphoblastic leukemia.
  • Adding dexrazoxane (DZR) to DOX treatment resulted in reduced myocardial injury in children with acute lymphoblastic leukemia (ALL) during Dana-Farber Cancer Institute Protocol 95-01.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962530.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Lonetti A, Iacobucci I, Ferrari A, Messina M, Cilloni D, Soverini S, Papayannidis C, Baccarani M, Foà R, Martinelli G: Expression of different isoforms of the B-cell mutator activation-induced cytidine deaminase (AID) in BCR-ABL1-positive acute lymphoblastic leukemia (ALL) patients. J Clin Oncol; 2009 May 20;27(15_suppl):7049

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of different isoforms of the B-cell mutator activation-induced cytidine deaminase (AID) in BCR-ABL1-positive acute lymphoblastic leukemia (ALL) patients.
  • : 7049 Since the activation-induced cytidine deaminase (AID) enzyme can target non-immunoglobulin (Ig) genes and may even act as a genome-wide mutator, we investigated AID expression in BCR-ABL1-positive ALL and in chronic myeloid leukemia (CML) at the time of progression to blast crisis.
  • On the 61 de novo adult BCR-ABL1-positive ALL patients (pts), AID mRNA and protein were detected in 36 (59%); their expression correlated with BCR-ABL1 transcript levels and disappeared after treatment with tyrosine kinase inhibitors at the time of remission.
  • AID expression was also found in lymphoid blast crisis CML (50%), but not in myeloid lineage or in chronic phase CML.
  • Our findings show that BCR-ABL1-positive ALL cells aberrantly express different isoforms of AID that can act as mutator outside the Ig gene loci in promoting genetic instability in leukemia cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961429.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Hanrahan EO, Kim F, Lin HY, Tran HT, Ryan AJ, Krebs AD, Lee JJ, Johnson BE, Heymach JV, Kim ES: Plasma cytokine concentrations and quality of life in patients with non-small cell lung cancer in a phase II trial of first-line treatment with carboplatin-paclitaxel and/or vandetanib. J Clin Oncol; 2009 May 20;27(15_suppl):9596

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma cytokine concentrations and quality of life in patients with non-small cell lung cancer in a phase II trial of first-line treatment with carboplatin-paclitaxel and/or vandetanib.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963731.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Kiers HA: Properties of and Algorithms for Fitting Three-Way Component Models with Offset Terms. Psychometrika; 2006 Jun;71(2):231-256

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Properties of and Algorithms for Fitting Three-Way Component Models with Offset Terms.
  • : Prior to a three-way component analysis of a three-way data set, it is customary to preprocess the data by centering and/or rescaling them.
  • Harshman and Lundy (1984) considered that three-way data actually consist of a three-way model part, which in fact pertains to ratio scale measurements, as well as additive "offset" terms that turn the ratio scale measurements into interval scale measurements.
  • They mentioned that such offset terms might be estimated by incorporating additional components in the model, but discarded this idea in favor of an approach to remove such terms from the model by means of centering.
  • Then estimates for the three-way component model parameters are obtained by analyzing the centered data.
  • In the present paper, the possibility of actually estimating the offset terms is taken up again.
  • First, it is mentioned in which cases such offset terms can be estimated uniquely.
  • Next, procedures are offered for estimating model parameters and offset parameters simultaneously, as well as successively (i.e., providing offset term estimates after the three-way model parameters have been estimated in the traditional way on the basis of the centered data).
  • These procedures are provided for both the CANDECOMP/PARAFAC model and the Tucker3 model extended with offset terms.
  • The successive and the simultaneous approaches for estimating model and offset parameters have been compared on the basis of simulated data.
  • It was found that both procedures perform well when the fitted model captures at least all offset terms actually underlying the data.
  • The simultaneous procedures performed slightly better than the successive procedures.
  • If fewer offset terms are fitted than there are underlying the model, the results are considerably poorer, but in these cases the successive procedures performed better than the simultaneous ones.
  • All in all, it can be concluded that the traditional approach for estimating model parameters can hardly be improved upon, and that offset terms can sufficiently well be estimated by the proposed successive approach, which is a simple extension of the traditional approach.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28197950.001).
  • [ISSN] 1860-0980
  • [Journal-full-title] Psychometrika
  • [ISO-abbreviation] Psychometrika
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; additive terms / preprocessing / three-way component models
  •  go-up   go-down


80. Lin C, Moore D, DeMichele A, Ollila D, Montgomery L, Liu M, Krontiras H, Gomez R, Esserman L, I-SPY TRIAL Investigators: Detection of locally advanced breast cancer in the I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657) in the interval between routine screening. J Clin Oncol; 2009 May 20;27(15_suppl):1503

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of locally advanced breast cancer in the I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657) in the interval between routine screening.
  • : 1503 Background: It is assumed that most locally advanced breast cancers (LABC) could be detected at an earlier stage with routine screening.
  • However, LABCs may present between screens as interval cancers (IC).
  • ICs present at an earlier age, with higher grade, larger size, and are associated with lower survival, compared to screen-detected cancers (SDC), and comprise 17% of cancers from population-based screening programs.
  • We evaluated the screening history in patients with LABCs from the I SPY TRIAL, to determine the frequency of screening and ICs.
  • METHODS: Of 221 pts enrolled in the I-SPY TRIAL, a multisite neoadjuvant study for women with LABCs > 3cm in size, screening history and presentation were retrospectively collected for 154.
  • Two groups, screened (S), defined as a mammogram within 2 years, or non screened (NS), previous mammogram more than 2 years prior, were evaluated (Table).
  • The frequency of ICs at 1 and 2 years was determined in S pts.
  • Frequency of mammographically occult (MO) tumors was determined for all.
  • RESULTS: Of the total, 99 (64%) and 55 (36%) were NS and S, respectively.
  • Mean tumor size for all pts was 6.7cm.
  • Only 11 (20%) of S pts were SDCs and 44 (80%) were ICs, with 24 (63%) diagnosed within 1 year and 14 (37%) between 1 and 2 yrs of their last normal mammogram.
  • 24 (24%) NS patients were younger than the recommended screening age of 40; in the remaining 75 pts, 9 (12%) were MO.
  • Only 20% of IC tumors were MO.
  • ICs were of higher grade (44% vs 11% grade III), and tumor size (7.0cm vs 4.4cm) than their SDC counterparts.
  • 80% of cancers detected in I SPY were NKI70 gene test poor prognosis.
  • Relationship to breast density and subtype is currently being assessed.
  • CONCLUSIONS: Women presenting with LABCs have a high likelihood (80%) of an IC.
  • This suggests that the growth rate of LABCs precludes early detection by conventional screening.
  • Understanding the biology of ICs will be important to develop better strategies for prevention and early detection.
  • [Table: see text] No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964313.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Procopio G, Verzoni E, Bracarda S, Ricci S, Sacco C, Ridolfi L, Porta C, Miceli R, Zilembo N, Bajetta E, ITMO Study Group: A randomized, open label, prospective study comparing the association between sorafenib (So) and interleukin-2 (IL-2) versus So alone in advanced untreated renal cell cancer (RCC): Rosorc Trial. J Clin Oncol; 2009 May 20;27(15_suppl):5099

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized, open label, prospective study comparing the association between sorafenib (So) and interleukin-2 (IL-2) versus So alone in advanced untreated renal cell cancer (RCC): Rosorc Trial.
  • Therapy continued until progression of disease or unacceptable toxicity.
  • Eligible pts had histological diagnosis of RCC, ECOG 0-2, no brain metastases, measurable disease and any Motzer's score.
  • Overall disease control rates (PR + stable disease SD) were 81 % versus 74 %.
  • CONCLUSIONS: The safety and efficacy data suggest that the association So + IL-2 is safe and feasible and, compared to So alone, improves tumour shrinkage, disease control rate and PFS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964308.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Goldman S, Coiffier B, Reiter A, Younes A, Cairo MS, International TLS Expert Panel: A medical decision tree for the prophylaxis (P) and treatment (T) of tumor lysis syndrome (TLS): An international TLS consensus panel. J Clin Oncol; 2009 May 20;27(15_suppl):e17575

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 2008) Results: Patients without evidence of LTLS were assigned to either low-risk disease (LRD), medium-risk (MRD), or high-risk (HRD).
  • Risk factors included pathological classification stage, bulk, disease burden (WBC/LDH) and renal impairment/involvement.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963935.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Blay J, Penel N, Italiano A, Duffaud F, Rios M, Collard O, Bertucci F, Isambert N, Chaigneau L, Zintl P: Trabectedin for advanced sarcomas failing doxorubicin: Analysis of 189 unreported patients in a compassionate use program. J Clin Oncol; 2009 May 20;27(15_suppl):10574

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trabectedin for advanced sarcomas failing doxorubicin: Analysis of 189 unreported patients in a compassionate use program.
  • : 10574 Background: Between 2005 and 2008, 387 patients (pts) with advanced sarcoma failing doxorubicin were treated in a compassionate use program (ATU) of trabectedin in France using the standard 1.5mg/m2/CI 24h q21d regimen.
  • The purpose of this study was to assess the outcome of pts treated in this program.
  • METHODS: From 2005 to 2008, 87 centers (ctrs) included at least 1 pt in the ATU program.
  • Inclusion criteria were those of the EORTC trial (J Clin Oncol, 2005;23:5276), with no restriction on the previous number of lines.
  • A simple CRF with 22 items was used to collect pts characteristics and outcome.
  • One hundred eighty-nine pts files were collected as of December 20, 2008.
  • Univariate and multivariate analyses of prognostic factors was performed.
  • RESULTS: Two hundred thirty-five pts were included in the 17 ctrs in which >4 pts were treated.
  • Forty-four ctrs treated only 1 pt.
  • Fifty-two percent were female; major histological subgroups were leiomyosarcoma (29%) and liposarcoma (20%).
  • All pts had been treated with doxorubicin and ifosfamide, 3 (1.5%) in adjuvant setting only.
  • Trabectedin was given in 1st, 2nd, 3rd, or 4th line in metastatic phase in n=8, 69, 66, 42 pts respectively (median: 3rd line).
  • The median number of courses were 3 (range 1-24).
  • Best response reported were PR, n=15 (8%), SD, n=68 (36%) and PD, n=94 (50%), NE, n=11 (6%).
  • With a median follow-up of 805 days (d), median PFS and OS were 91 d and 309 d respectively.
  • 27/127 (20%) evaluable pts had to be hospitalized for treatment related side effects.
  • PFS was superior in myxoid liposarcoma (MyxLPS) (median 192 d vs 69 d, p=0.003), retroperitoneal sarcomas (median 104 d vs 69 d, p=0.006), and grade 1 tumors (median 141 d vs 70 d, p=0.01).
  • In multivariate analysis (Cox model), tumor site, grade 1, histotype were the only independent prognostic factors for PFS.
  • For OS, favorable prognostic factors in univariate analysis were histotypes (MyxLPS, MFH), grade 1 lesions, retroperitoneal site, no hospitalisation for toxicity (p<0.01 all) while Cox model identified female gender, tumor site, histotype as the only independent prognostic factors for OS.
  • CONCLUSIONS: In this compassionate use program for heavily pretreated pts with advanced sarcomas, trabectedin yielded PFS and OS close to those observed in phase II and III trial.
  • PFS and OS are superior in myxLPS, retroperitoneal sarcomas, and grade 1 tumors.
  • [Table: see text].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963783.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Dookeran KA, Dignam J, Ferrer K, Sekosan M, McCaskill-Stevens W, Gehlert S: p53 as a marker of prognosis in African American (AA) women with breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e22119

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p53 as a marker of prognosis in African American (AA) women with breast cancer.
  • : e22119 Background: Prior reports suggest that p53 may be of prognostic value in AA women with breast cancer.
  • However, it remains to be determined whether p53 status would add prognostic value beyond the commonly used factors of stage and Intrinsic Subtype Classification (subtype).
  • We evaluated p53 status as a prognostic factor among AA women treated at an urban community hospital.
  • METHODS: Cox proportional hazards regression models [results reported as hazard ratios (HR) with 95% confidence intervals (CI)] were used to select and evaluate prognostic factors [including stage, age, tumor grade of differentiation (grade), p53 status, subtype, & ER/PR status] for all-cause mortality in 331 consecutively treated AA women with breast cancer [42 months follow-up] and known subtype [luminal A = ER+, &/or PR+, & HER2-; luminal B = ER+, &/or PR+, & HER2+; HER2+ = ER-, PR-, & HER2+; basal = ER-, PR-, HER2-, cytokeratin (CK) 5/6+ &/or HER1+; & unclassified = negative for all 5 markers] and p53 [Pab1801 antibody] immunohistochemical status.
  • RESULTS: Tumors in 28% of women were p53+ and there were no chemotherapy and radiation treatment differences according to p53 status.
  • However, 59% of p53+ women were ER/PR negative [Odds Ratio (OR), 0.37; 95% CI, 0.22-0.54; p=0.0003] and hence endocrine therapy was significantly less frequent in p53+ women [OR, 0.40; 95% CI, 0.23-0.69; p=0.0008].
  • p53+ tumors were also significantly more likely to be grade 3 [OR, 4.35; CI, 1.33-14.14; p=0.013].
  • Baseline prognostic factors were: stage [(II-IV/I) HR, 2.29; 95% CI, 1.86-2.81; p<0.0001]; age [HR, 1.003 per year; 95% CI, 0.99-1.02; p=0.697]; grade [(high/low) HR, 1.70; 95% CI, 1.22-2.37; p=0.0008]; p53 status [(±) HR, 1.76; 95% CI, 1.15-2.72; p=0.012]; subtype [(all other/luminal A) HR, 1.33; 95% CI, 1.14-1.55; p=0.0004]; ER/PR status [(±) HR, 0.47; 95% CI, 0.32-0.69; p=0.0001].
  • Cox multivariable models indicated that p53 status [HR, 1.59; 95% CI, 1.01-2.51; p=0.044] remained a significant prognostic factor when considered with stage [HR, 2.20; 95% CI, 1.71-2.84; p<0.001] and subtype [HR, 1.24; 95% CI, 1.04-1.49; p=0.016] and the other above-mentioned factors.
  • CONCLUSIONS: Study results indicate that p53 status should be included with stage and subtype as markers to assess prognosis in AA women with breast cancer.
  • No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963516.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Hensel M, Goetzenich A, Hanhoff N, Wolf E, Knechten H, Mosthaf F: Cancer incidence in HIV-positive patients in Germany: A nation-wide survey from 2000 to 2007. J Clin Oncol; 2009 May 20;27(15_suppl):e22115

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The questionnaire requested information on all malignancies in HIV-positive pts, tumor stage, CDC (Center for Disease Control)-stage of the HIV infection, sex, treatment and clinical course.
  • The majority of pts had advanced HIV-disease (CDC stage C3), but the proportion of pts with stage C3 decreased from 58% in 2000 to 36.8% in 2007.
  • 253 (45.8%) were AD as follows: 132 Kaposi Sarcomas, 109 aggressive B-cell lymphomas, 12 invasive cervix carcinomas.
  • The B-cell lymphomas further included 28 Burkitt's lymphomas, 30 DLBCL, 9 Castleman diseases, 8 primary cerebral lymphomas.
  • The number of pts with Hodgkin's lymphoma has increased constantly from 2000 to 2007.
  • The incidence of primary cerebral lymphomas seems to decrease, whereas the incidence of Hodgkin's lymphoma is increasing.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963512.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Godoy J, Cardona AF, Cáceres H, Otero JM, Lujan M, Lopera D, Pacheco JO, Spath A, Gis P: Cost-effectiveness analysis of first-line treatment for metastatic renal cell carcinoma (mRCC) in Colombia (ONCOLGroup study). J Clin Oncol; 2009 May 20;27(15_suppl):e16150

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost-effectiveness analysis of first-line treatment for metastatic renal cell carcinoma (mRCC) in Colombia (ONCOLGroup study).
  • : e16150 Background: Renal cell carcinoma has increased its incidence by 126% since 1950.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963418.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Kolinsky KD, Zhang Y, Packman K, Higgins B: In vivo activity of R1530 (R) alone and in combination with docetaxel (D) and bevacizumab (B) in a prostate carcinoma (PCa) xenograft model. J Clin Oncol; 2009 May 20;27(15_suppl):e16124

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Its inhibitory profile includes several kinases that play critical roles in cancer cell growth and division leading to disruption at M-phase and antiangiogenic effects.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963395.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Feldman DR, Sheinfeld J, Bajorin DF, Fischer P, Turkula S, Ishill N, Patil S, Bains M, Bosl GJ, Motzer RJ: Paclitaxel (T) plus ifosfamide (I) followed by high-dose carboplatin (C) and etoposide (E) with autologous stem cell support for patients (pts) with previously treated germ cell tumors (GCT): TI-CE results and prognostic factor analysis in 107 pts. J Clin Oncol; 2009 May 20;27(15_suppl):5027

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel (T) plus ifosfamide (I) followed by high-dose carboplatin (C) and etoposide (E) with autologous stem cell support for patients (pts) with previously treated germ cell tumors (GCT): TI-CE results and prognostic factor analysis in 107 pts.
  • METHODS: Phase I/II trial of TI-CE conducted in GCT pts with progressive disease following chemotherapy and unfavorable prognostic features (extragonadal primary site, IR to first-line therapy, or relapse/IR to ifosfamide/cisplatin-based conventional-dose salvage).
  • 5-yr disease-free survival (DFS) was 47% and overall survival 52% with a median follow-up of 61 months (m).
  • 5/21 (24%) primary mediastinal NSGCT and 2/7 late relapses are continuously disease-free.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962915.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Colucci G, Labianca R, Di Costanzo F, Gebbia V, Cartenì G, Massidda B, Frontini L, Falconi M, Gallo C, Di Maio M: A randomized trial of gemcitabine (G) versus G plus cisplatin in chemotherapy-naive advanced pancreatic adenocarcinoma: The GIP-1 (Gruppo Italiano Pancreas- GOIM/GISCAD/GOIRC) study. J Clin Oncol; 2009 May 20;27(15_suppl):4504

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized trial of gemcitabine (G) versus G plus cisplatin in chemotherapy-naive advanced pancreatic adenocarcinoma: The GIP-1 (Gruppo Italiano Pancreas- GOIM/GISCAD/GOIRC) study.
  • : 4504 Background: Single-agent gemcitabine (G) remains standard treatment for advanced pancreatic adenocarcinoma (APC).
  • The GIP-1 randomized phase III trial (clinicaltrials.gov ID NCT00813696 ) was performed to compare the combination of cisplatin (P) and G vs. G alone as 1st-line treatment.
  • METHODS: Patients (pts) with locally advanced and/or metastatic pancreatic adenocarcinoma, age 18-75, Karnofsky Performance Status (KPS) ≥50, were randomized to receive G (arm A) or G+P (arm B).
  • In arm A, G was administered at 1000 mg/m2 weekly for 7 consecutive wks, and, after a 2-week rest, on day 1, 8, 15 every 4 wks.
  • In Arm B, P 25 mg/m2 weekly (with the exception of day 22) was added to G, same dose used in Arm A (Colucci et al, Cancer 2002; 94:902-10).
  • No maximum number of cycles was planned.
  • Primary endpoint was overall survival (OS).
  • Clinical benefit (CB), objective response rate (ORR), progression-free survival (PFS), toxicity and quality of life were secondary endpoints.
  • To have 80% power of detecting a 0.74 Hazard Ratio (HR) of death (corresponding to increase in median OS from 4.8 to 6.5 months, with bilateral alpha=0.05, 400 pts were planned and 355 deaths were required for final analysis.
  • RESULTS: From April 2002 to April 2007, 400 pts were enrolled (A:199, B;.
  • 201) in 46 Italian Institutions.
  • Median age was 63 yrs (range 35-75), 59% were males, 84% stage IV, 83% KPS≥80.
  • After a median follow-up of 38.2 months and 357 deaths, median OS was 8.3 vs 7.2 months in arm A and B, respectively (HR 1.10, 95% CI 0.89-1.35, p=0.38).
  • Median PFS was 3.9 vs 3.8 months in arm A and B, respectively (HR 0.97, 95% CI 0.80-1.19, p=0.80).
  • ORR was 10.1% in arm A and 12.9% in B (p=0.37).
  • CB response was experienced by 23.0% and 15.1% (Arm A vs B, p=0.057).
  • Patients assigned to combination arm experienced more anaemia (all grades: 50% vs 39%, G3: 5% vs 1%), more neutropenia (all grades: 44% vs 36%, G3&4: 25% vs 14%) and more thrombocytopenia (all grades: 57% vs 29%, G3&4: 16% vs 5%).
  • No relevant differences were seen in non-haematological toxicity.
  • CONCLUSIONS: Weekly combination of P and G, compared to single-agent G as 1st-line treatment of APC, failed to demonstrate any improvement in OS, PFS, ORR and clinical benefit.
  • No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962688.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Stein MN, Knox B, Wesolowsky E, Levitt M, Moss R, Poplin E, Mehnert J, Gounder M, Goodin S, DiPaola R: Phase I trial of patupilone (P) and RAD001 in patients (pts) with advanced solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):2529

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In pts with prostate cancer (all previously pretreated with D) PSA declines of >50% occurred in 3/5 pts treated with >2 cycles; 1/7 pts with colon cancer had a PR and 3/7 pts with colon cancer had stable disease (SD) > 8 cycles; 1/3 pts with ampullary ca had a PR and a pt with cervical ca had SD x10 cycles.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961847.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Mishra A, Singh VP, Verma V: Environmental effects on head and neck cancer in India. J Clin Oncol; 2009 May 20;27(15_suppl):e17059

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Environmental effects on head and neck cancer in India.
  • : e17059 Background: Head and neck cancer in India has unique demographic profile, environmental exposure, dietary habits, and personal and family history.
  • METHODS: 1,000 cases were analysed.
  • RESULTS: Males dominated (82%) in fifth (29%) and sixth (33%) decades.
  • Majority was uneducated (76%) and poor.
  • Passive tobacco smoking was seen in-house (85%) as well as in the work-place (80%).
  • Approximately 69% smoked more than 100 cigarettes/bidis in their lifetime.
  • Majority acquired regular smoking habit in second (73%) and third (18%) decades and continued smoking for more than 20 years (66%) with 10-20 cigarettes daily (range 1 to 43).
  • However 30% never used tobacco.
  • The main alternative forms were bidi (27%) and smokeless-tobacco chewing products (47%).
  • A past history of cancer and the subsequent radiation treatment was found in 3% while GERD in 33%.
  • Multivitamins/minerals for chemoprevention was used in 65% for 1 to 12 months.
  • Alcohol consumption was seen in 26% where the age of initiation was in second and third decade and the total years of consumption mainly varied from 10-30 years.
  • Having a predominant agriculture-based-economy, the majority of males (38%) were farmers with significant exposure to pesticides and fertilizers; while females predominantly housewifes (17%).
  • The family history was appreciated in 1% with natural parents known in all.
  • The most common sites involved were oral cavity (28%), oropharynx (30%), and larynx (32%).
  • Majority presented with advanced stage (III = 39%; IV = 23%).
  • The consumption of fruit and vegetable juice was less common as compared to fresh consumption as such.
  • Green salads, potatoes, and fiber cereals were significantly used (4-6 times a week).
  • Beans, peas, and corn was not common while beef and pork consumption rare owing .
  • The 'staple' diet was wheat, rice, pulses with additional meat mainly in Muslims (once a day).
  • The use of cooking oil, butter, eggs biscuits, cheese, cakes, and cookies was uncommon (less than once a week), but milk was abundant.
  • CONCLUSIONS: Hence, it seems that poor, education/literacy, poor socioeconomic status, tobacco smoking (passive and active) at an early age for prolonged duration, tobacco-related products and exposure to pesticides/fertilizers predispose Indian population for head and neck cancer, rather than a positive family history, dietary factors, radiation exposure, or alcoholism.
  • No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961820.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Costello BA, Hecht JR, Grothey A: Progression-free survival in intention to treat populations versus total KRAS populations in patients treated for metastatic colorectal cancer: A pooled review. J Clin Oncol; 2009 May 20;27(15_suppl):4054

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progression-free survival in intention to treat populations versus total KRAS populations in patients treated for metastatic colorectal cancer: A pooled review.
  • : 4054 Background: In treatment trials of patients with metastatic colorectal cancer (mCRC), KRAS mutation status of tumor samples has been retrospectively demonstrated to be predictive of treatment benefit.
  • Historically, clinical trials have not required tissue samples to be tested for KRAS mutation status as a condition of enrollment.
  • Therefore, KRAS analyses have been based on available tissue samples representing only a portion of patients retrospectively analyzed for KRAS status and correlated with treatment end- points.
  • METHODS: A weighted analysis of pooled data was performed using six recently presented or published clinical trials of targeted therapy in mCRC which tested for the association of KRAS status with Progression Free Survival (PFS).
  • The goal of the analysis was to determine whether there is a significant difference in PFS between the intention to treat (ITT) population and KRAS population in both the treatment and control arms.
  • RESULTS: The total ITT population of the pooled studies is 3864, and for the total KRAS population, 2295; a 59.4% retrieval rate (range 28-92%) for tissue samples available for KRAS analysis.
  • The weighted Δ PFS across all arms between the ITT population and the KRAS population was 0.2 months with a range of 0-0.7 months.
  • Of the 12 subgroups (6 control and 6 treatment arms), five had no difference in PFS between ITT and KRAS evaluable populations at all, and two additional subgroups demonstrated a difference PFS of only 0.1 months.
  • The two studies with the lowest tissue retrieval rates (28% and 45%) had the largest Δ PFS.
  • CONCLUSIONS: There is no meaningful difference in the PFS between the ITT and KRAS populations based on our analysis of pooled data.
  • The difference in PFS was greatest in the two studies with the lowest rate of retrieval of tissue samples for KRAS testing.
  • As such, subgroup analysis is better able to estimate and reflect the ITT population if a higher percentage of samples is able to be obtained.
  • Further, our results suggest that there is not an inherent systemic bias influencing any potentially observed differences in PFS.
  • Tissue samples should be required for all patients entering a clinical trial to avoid this issue and to make retrospective analysis more valid.
  • [Table: see text].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961588.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Besse B, Almokadem S, Planchard D, Chico I, Tsao CL, Ringeisen F, Soria J, Belani CP: Safety and early efficacy results from a phase I study of volociximab (V) in combination with carboplatin (C) and paclitaxel (P) in patients (pts) with advanced non small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):e13513

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and early efficacy results from a phase I study of volociximab (V) in combination with carboplatin (C) and paclitaxel (P) in patients (pts) with advanced non small cell lung cancer (NSCLC).
  • Partial response was seen in 6 pts and stable disease in 12 out of 18 pts who were evaluable for response by RECIST.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961304.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Dhruva NS, Stinchcombe TE, Walko CM, Socinski MA, Bernard S, Kim WY, Keller K, Hilbun LR, Dees EC: Preliminary results of a phase I trial of sorafenib combined with cisplatin/etoposide (CE) or carboplatin/pemetrexed (CbP) in solid tumor patients (pts). J Clin Oncol; 2009 May 20;27(15_suppl):e13521

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e13521 Background: Sorafenib had demonstrated single agent activity in non-small cell and small cell lung cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961275.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Ray-Coquard IL, Provençal J, Hardy-Bessard AC, Bachelot T, Coeffic D, Jacquin JP, Guastalla JP, Agostini C, Pivot X, Bajard A, Pérol D: Can adjuvant homeopathy improve the control of post-chemotherapy emesis in breast cancer patients? Results of a randomized placebo-controlled trial. J Clin Oncol; 2009 May 20;27(15_suppl):e20566

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can adjuvant homeopathy improve the control of post-chemotherapy emesis in breast cancer patients? Results of a randomized placebo-controlled trial.
  • : e20566 Background: Homeopathy used as an adjunct in the treatment of chemotherapy (CT)-induced emesis has rarely been evaluated.
  • METHODS: Patients with non-metastatic breast cancer treated with 6 courses of FAC 50, FEC 100 or TAC chemotherapy were randomized to Cocculus/nux vomica/tabacum/petroleum extract (Cocculine, C) or Placebo (P) in a multicentric comparative double-blind phase III study.
  • Anti-emetic treatment was standardized (corticoids + ondansetron).
  • Patients were evaluated after each course.
  • The primary endpoint was nausea measured after the 1<sup>st</sup> CT course using the FLIE (Functional Living Index for Emesis) with 5-day recall.
  • The planned sample size was 396 evaluable patients based on a minimum expected difference in mean of 0.5 ± 1.6 on a scale from 1 (a lot) to 7 (not at all) with 5% two-sided α error and 85% power.
  • An intent-to-treat analysis was planned.
  • Secondary evaluation criteria were: vomiting measured by the FLIE score, patient self-evaluation (EVA) and investigator recording (NCI-CTC) of nausea and vomiting intensities, and compliance.
  • RESULTS: From September 05 to January 08, 431 patients were randomized (217 to P and 214 to C).
  • Patient characteristics were well balanced between groups.
  • Median age was 53 years, 35% of the patients experienced nausea or vomiting.
  • In total, 403 patients (93.5%) were assessable for the primary endpoint, with few nausea episodes (FLIE nausea scores after the 1<sup>st</sup> CT course were 6.02 and 6.07 for P and C, respectively) and very good compliance (81% patients complied with the protocol).
  • Adverse events related to nausea occurred in 51% vs. 47% of the patients treated with P and C, respectively (p = 0.48).
  • FLIE and NCI-CTC vomiting scores were similar between the 2 arms (6.91 vs. 6.88, p = 0.47, and 20% vs. 21%, p = 0.73, for P and C, respectively).
  • Grade II-III nausea occurred in 17.6% and 15.7% of patients receiving P and C (p = 0.62).
  • CONCLUSIONS: No benefit of homeopathy over standard treatment was noted in this study.
  • But surprisingly we observed lower rates of nausea and vomiting measured by patients and by investigators, than in other studies using identical chemotherapy regimens.
  • The observation and management of emesis could modify the perception and rate of such adverse events.
  • No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961132.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Spencer A, Taylor K, Lonial S, Mateos MV, Jalaluddin M, Hazell K, Bourquelot PM, San Miguel JF: Panobinostat plus lenalidomide and dexamethasone phase I trial in multiple myeloma (MM). J Clin Oncol; 2009 May 20;27(15_suppl):8542

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Panobinostat plus lenalidomide and dexamethasone phase I trial in multiple myeloma (MM).
  • : 8542 Background: Panobinostat (LBH589) is a highly potent pan-deacetylase inhibitor (pan-DACi), affecting with epigenetic and non-epigenetic pathways of cancer.
  • In vivo experiments demonstrated potent MM cytotoxicity of the triplet panobinostat + lenalidomide + dexamethasone.
  • METHODS: Trial started with 5 mg panobinostat (po, TIW) combined with fixed doses of lenalidomide (25 mg po, QD, Days 1-21) and dexamethasone (40 mg po, Days 1-4, 9-12, 17-20, Cycles 1-4), in a 28-day cycle.
  • MTD of panobinostat in this combination for second-line MM will be established based on data from cohorts of ≥6 evaluable patients (pts).
  • Safety, tolerability, PK/PD, and preliminary efficacy will be assessed.
  • RESULTS: Twenty-two pts with relapsed or relapsed refractory MM were treated in three dose levels to date.
  • Dose escalation started at 5 mg panobinostat (po, thrice weekly) combined with fixed doses of 25 mg lenalidomide (po, qd, Days 1-21) and 40 mg of dexamethasone (po, Days 1-4, 9-12, 17-20, Cycles 1-4), in a 28-day cycle.
  • Data from all eight patients in Cohort 1 were evaluated.
  • The median number of prior lines of therapy was two (range 1-3).
  • Six out of eight patients in Cohort 1 remain on therapy.
  • Median follow-up is six cycles (range 4-8+).
  • No DLT was observed.
  • In Cohort 2, eight patients were treated at the dose level of 10 mg of panobinostat, with one single DLT: a Gr 1 increase of QT interval duration was detected on Day 3, persisting on Day 8 with therapy withheld, meeting DLT definition although not deemed clinically relevant.
  • Cohort 3 is enrolling with six patients at 20 mg of panobinostat, thus far.
  • SAEs included fever (two pts), anxious depressive syndrome, respiratory infection, atrial fibrillation, exertional dyspnea, cellulitis, superficial blood clot of thigh, phlebitis, hypokalemia.
  • All, but fever in one patient, were assessed by the investigator as not study drug related.
  • CONCLUSIONS: The potential for anti-myeloma activity of this triple combination is strongly supported by in vivo preclinical data.
  • In this first clinical trial assessing this triple oral combination, the 5 and 10 mg dose level of panobinostat appear safe.
  • Updated safety, early efficacy, and subsequent dose-level patient data will be presented.
  • [Table: see text].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960957.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Samelis GF, Tsiakou A, Karamanidi M, Pelechrini M, Zaganides A, Ekmektzoglou K: Effect of continuation of bevacizumab following disease progression in patients with metastatic colorectal cancer on survival. J Clin Oncol; 2009 May 20;27(15_suppl):e15143

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of continuation of bevacizumab following disease progression in patients with metastatic colorectal cancer on survival.
  • Bevacizumab treatment was continuously dispensed after disease progression and only other combined drugs were altered.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960881.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Evens AM, David KA, Helenowski I, Kircher SM, Mauro L, Gimelfarb A, Hattersley E, Shammo JM, Smith SE, Smith SM: Multicenter analysis of 81 solid organ transplant (SOT) recipients with posttransplantation lymphoproliferative disease (PTLD): Examination of survival and prognostic factors. J Clin Oncol; 2009 May 20;27(15_suppl):8510

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicenter analysis of 81 solid organ transplant (SOT) recipients with posttransplantation lymphoproliferative disease (PTLD): Examination of survival and prognostic factors.
  • RESULTS: 81 PTLD pts were identified (SOT: 47 kidney ± pancreas, 4 pancreas, 17 liver, 8 heart, 5 lung) with median age at diagnosis (dx) of 48 yrs (range 20-72).
  • 1) PS, 2) serum albumin, 3) >1 EN site, 4) marrow involvement, 5) CNS disease and 6) RTX as part of initial therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960875.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Piura E, Chapman JW, Lipton A, Zhu L, Leitzel K, Wilson CF, Pritchard KI, Shepherd L, Pollak MN: Serum 1-OH vitamin D (D) and prognosis of postmenopausal breast cancer (BC) patients: NCIC-CTG MA14 trial. J Clin Oncol; 2009 May 20;27(15_suppl):534

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recurrence-free survival (RFS), time from randomization to recurrence of the primary disease alone, was a secondary endpoint.
  • As expected, D levels for a population far from the equator varied with month of blood draw (p = 0.007), which gives confidence in assay performance.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960688.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement